ABHD6 antagonist

MYPI2025001727A0Undetermined Publication Date: 2024-03-30ONO PHARMA CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI2025001727
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-09-30
Filing Date
2023-09-29
Publication Date
2024-03-30

AI Technical Summary

Technical Problem

Current technologies lack a compound with specific ABHD6 inhibitory activity, which is crucial for addressing neurological and inflammatory diseases without causing central side effects associated with cannabinoid system activation.

Method used

Development of a compound represented by general formula (I), which exhibits strong inhibitory activity against ABHD6, allowing for low excretion by P-glycoprotein and excellent central distribution, thereby serving as a preventive and/or therapeutic agent for diseases related to ABHD6.

Benefits of technology

The compound effectively inhibits ABHD6, providing neuroprotection and reducing neuroinflammation, making it suitable for treating various inflammatory and neurological diseases without central side effects.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

ABSTRACT ABHD6 ANTAGONIST A drug is provided, which containing, as an active ingredient, a compound having ABHD6 inhibitory activity in prevention and / or treatment of a disease associated with ABHD6. A compound represented by general formula (I) or a pharmaceutically acceptable salt thereof has ABHD6 inhibitory activity and therefore is useful as a pharmaceutical ingredient having potent ABHD6 inhibitory activity in the prevention and / or treatment of a disease associated with ABHD6: in which all symbols represent the same meaning as the symbols described in the specification.
Need to check novelty before this filing date? Find Prior Art

Description

ABHD6 antagonist

[0001] The present disclosure relates to a compound having ABHD6 inhibitory activity or a pharmaceutically acceptable salt thereof, and a pharmaceutical containing the compound or a salt thereof as an active ingredient. (wherein all symbols have the same meaning as defined below), or a pharmaceutically acceptable salt thereof (hereinafter referred to as the disclosed compound), and a pharmaceutical composition containing the same as an active ingredient.

[0002] ABHD6 (alpha / beta-Hydrolase domain containing 6) is a serine hydrolase and one of the metabolic enzymes of the endocannabinoid 2-arachidonoylglycerol (2-AG). 2-AG serves as an important lipid precursor in the eicosanoid signaling pathway and also functions as an endogenous signaling lipid for the activation of cannabinoid receptors 1 and 2 (CB1 and CB2, respectively). Therefore, ABHD6 and 2-AG are known to be involved in the regulation of various physiological processes, including pain sensation, neurotransmission, inflammation, insulin secretion, adipose browning, food intake, autoimmune disorders, neurological disorders, and metabolic diseases (Non-Patent Document 1).

[0003] Furthermore, it is known that inhibition of ABHD6 significantly reduces neuroinflammation and exerts neuroprotection in animal models of traumatic brain injury and multiple sclerosis. Therefore, inhibition of ABHD6 is thought to be useful for the prevention and / or treatment of various inflammatory and neurological diseases without causing central side effects caused by the cannabinoid system (Non-Patent Document 2).

[0004] On the other hand, Patent Document 1 describes that a compound represented by the following general formula (A) is a compound having mAChR receptor antagonist activity. (In the formula, ring A A represents a 5-6 membered heteroaryl ring having 1 to 3 heteroatoms selected from N, O and S; Q A is NR aA or O; mA represents 0, 1, or 2; R 1Ais heteroaryl, aryl, heterocyclyl, cycloalkyl, halogen, —OR bA , -NR cA R dA and NHCOR eA nA represents 1 or 2; R 2A is hydrogen, a C1-4 alkyl group, a halogen, and —OR fA is selected from R 3A is selected from hydrogen and a C1-4 alkyl group; R 4A is -(CR gA R hA ) pA -Y A R' is selected from hydrogen, a C alkyl group, and a C alkenyl group; 5A is selected from hydrogen, a C1-4 alkyl group, a halogen, a C1-4 haloalkyl group, a C1-4 alkoxy group, and a C1-4 haloalkoxy group; Y A ' is selected from cycloalkyl, cycloalkenyl, heterocycle, aryl, and heteroaryl; p A represents an integer of 0 to 4. (Partial excerpt of the group definitions)

[0005] Furthermore, Patent Document 2 discloses that the compound represented by the following general formula (B) is a compound having FAAH inhibitory activity. (In the formula, R 2B is hydrogen, fluorine, hydroxyl, cyano, trifluoromethyl, a C1-6 alkyl group, a C1-6 alkoxy group, or NR 8B R 9B represents a group, m B , n B , o B and p B are, independently of one another, numbers ranging from 0 to 3, and m B +o B and n B +p B represents a number such that each of the numbers is 4 or less, and A B represents a covalent bond, an oxygen atom, a C1-6 alkylene group or an —O—C1-6 alkylene group (in which case the terminus represented by the oxygen atom is replaced by a group R 1Band the end represented by the alkylene group is bonded to a carbon of the bicycle. 1B is unsubstituted or contains one or more R 6B and / or R 7B R is substituted with 5B represents R 5B represents a group selected from phenyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, naphthyl, quinolyl, isoquinolyl, phthalazinyl, quinazolinyl, quinoxalinyl, cinnolinyl, naphthyridinyl, benzothiazolyl, benzoxazolyl, benzimidazolyl, benzisothiazolyl, benzisoxazolyl, indazolyl and benzotriazolyl, R 3B represents a hydrogen atom, a fluorine atom, a C1-6 alkyl group or a trifluoromethyl group; R 4B represents a 5-membered heterocycle selected from furyl, pyrrolyl, thienyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyrazolyl, oxadiazolyl, thiadiazolyl, imidazole, triazolyl, and tetrazolyl (the definitions of the groups are partially excerpted).

[0006] Patent Document 3 also describes that the compound represented by the following general formula (C) is a compound having a Ca channel inhibitory effect. (In the formula, L 1C is C(O), S(O) 2 , S.O. 2 N (R 4C ), C(O)O or -(CR aC R bC ) mC - and R 1C is alkyl, G 1C , -CH(G 1C ) 2 , -(CR aC R bC ) mC -G 1C , -(CR aC R bC ) mC -CH(G 1C ) 2 , -(CR eC RfC ) nC -N(R 5C ) 2 , -(CR eC R fC ) nC -N(R 5C )—C(O)O(alkyl), —(CR eC R fC ) nC -N(R 5C )—C(O)(alkyl) or —(CR eC R fC ) nC -N(R 5C )-SO 2 R 6C or L 1C -R 1C are combined to form hydrogen, alkyl, hydroxyalkyl, G 1C or -CH(G 1C ) 2 and L 2C is -(CR cC R dC ) pC -, C(O), C(O)N(R 4C ), S(O) 2 , S.O. 2 N (R 5C ) or C(O)O, R 2C is alkyl, G 2C , -C(R cC ) (G 2C ) (G 3C ), -(CR cC R dC ) pC -G 2C , -(CR cC R dC ) pC -CH(G 2C ) (G 3C ), -(CR gC R hC ) qC -N(R 5C )—C(O)O(alkyl), —(CR gC R hC ) qC -N(R 5C )-C(O)O-G 2C , -(CR gC R hC )qC -N(R 5C )—C(O)(alkyl), —(CR gC R hC ) qC -N(R 5C )-SO 2 R 6C , -(CR gC R hC ) qC -N(R 4C ) (R 5C ), -(CR gC R hC ) qC -N(R 5C )—C(O)N(R 5C )-(alkyl) or -(CR gC R hC ) qC -N(R 5C )—C(O)N(R 5C )-G 2C or L 2C -R 2C are united to form alkyl, G 2C or -C(R cC ) (G 2C ) (G 3C ) and G 1C , G 2C and G 3C are each independently an aryl, cycloalkyl, cycloalkenyl, heteroaryl, or heterocycle; G 1C , G 2C and G 3C are each independently unsubstituted or substituted with 1, 2, 3, 4, or 5 substituents; G 1C is other than a quinoline, a quinazolinedione or a pyridopyrimidinedione; R 3C represents hydrogen, alkyl, haloalkyl, cycloalkyl, or cycloalkylalkyl. (Partial excerpts of the group definitions are given below.)

[0007] However, none of the prior art documents describes or suggests that the compounds of the present disclosure have ABHD6 inhibitory activity.

[0008] International Publication No. 2019 / 089676 Pamphlet International Publication No. 2010 / 130944 Pamphlet International Publication No. 2010 / 062927 Pamphlet

[0009] European Journal of Medicinal Chemistry, Vol. 198, Article No. 112353, 2020 (European Journal of Medicinal Chemistry 198 (2020) 112353) Journal of Neuroinflammation, Vol. 15, Article No. 9, 2018 (Journal of Neuroinflammation (2018) 15:9)

[0010] An object of the present invention is to provide a compound having inhibitory activity against ABHD6.

[0011] As a result of intensive research aimed at solving the above problems, the present inventors have found that a compound represented by the general formula (I) described below has a strong inhibitory activity against ABHD6. That is, in one aspect, the present disclosure provides: [1] a compound represented by the general formula (I): (In the formula, R 1 represents a halogen atom; 2 represents (1) a halogen atom, (2) a C1-6 alkyl group, (3) a C2-6 alkenyl group, (4) a C2-6 alkynyl group, (5) a C1-6 alkoxy group, (6) a C1-6 haloalkyl group, (7) a C2-6 haloalkenyl group, (8) a C2-6 haloalkynyl group, or (9) a C1-6 haloalkoxy group, wherein 1 to 2 carbon atoms in the C1-6 alkyl group, C2-6 alkenyl group, C2-6 alkynyl group, C1-6 alkoxy group, C1-6 haloalkyl group, C2-6 haloalkenyl group, C2-6 haloalkynyl group, or C1-6 haloalkoxy group are optionally replaced by nitrogen atoms or optionally oxidized sulfur atoms, and when m represents 2, multiple R 2 may be the same or different, and two R 2represents a C alkyl group, a C alkenyl group, a C alkynyl group, a C alkoxy group, a C haloalkyl group, a C haloalkenyl group, a C haloalkynyl group, or a C haloalkoxy group, it may form a 5- or 6-membered cyclic group together with the carbon atom to which it is attached, 3 represents (1) a halogen atom, (2) a C alkyl group, (3) a C alkenyl group, (4) a C alkynyl group, (5) a C alkoxy group, (6) a C haloalkyl group, (7) a C haloalkenyl group, (8) a C haloalkynyl group, (9) a C haloalkoxy group, or (10) a hydroxyl group; when n is 2 or more, a plurality of R 3 may be the same or different, and two R 3 represents a C1-6 alkyl group, it may be taken together with the carbon atom to which it is attached to form a C3-6 cycloalkyl group, ring1 represents a 3- to 15-membered cyclic group, R 4 is (1) a halogen atom, (2) a C1-6 alkyl group, (3) a C2-6 alkenyl group, (4) a C2-6 alkynyl group, (5) a C1-6 alkoxy group, (6) a C1-6 haloalkyl group, (7) a C2-6 haloalkenyl group, (8) a C2-6 haloalkynyl group, (9) a C1-6 haloalkoxy group, (10) a C1-6 alkylthio group, (11) a C1-6 alkylsulfinyl group, (12) a C1-6 alkylsulfonyl group, (13) a C2-6 acyl group, (14) a 3- to 6-membered cyclic group, (15) -L R4 -(3- to 6-membered cyclic group), (16) hydroxyl group, (17) nitro group, (18) cyano group, (19) oxo group, (20) -NR 401 R 402 , (21)-COOR 403 , (22)-CONR 404 R 405 , or (23)-SO 2 NR 406 R 407wherein 1 to 2 carbon atoms in the C1-6 alkyl group, C2-6 alkenyl group, C2-6 alkynyl group, C1-6 alkoxy group, C1-6 haloalkyl group, C2-6 haloalkenyl group, C2-6 haloalkynyl group, C1-6 haloalkoxy group, C1-6 alkylthio group, C1-6 alkylsulfinyl group, C1-6 alkylsulfonyl group, or C2-6 acyl group may be replaced by an oxygen atom or an optionally oxidized sulfur atom, and when p is 2 or more, a plurality of R 4 may be the same or different, R 4 Among these, groups (2) to (15) are each a group having 1 to 9 R 408 and R 408 is (1) a halogen atom, (2) a C1-4 alkyl group, (3) a C1-4 alkoxy group, (4) a C2-6 acyl group, (5) a C3-6 cycloalkyl group, (6) a hydroxyl group, or (7) -NR 409 R 410 represents R 408 When two or more R are substituted, 408 may be the same or different, and L R4 (1) -O-, (2) -(C1-4 alkylene)-, (3) -O-(C1-4 alkylene)-, (4) -(C1-4 alkylene)-O-, (5) -NR 411 -, (6) -S-, (7) -SO-, or (8) -SO 2 represents -, R 401 , R 402 , R 403 , R 404 , R 405 , R 406 , R 407 , R 409 , R 410 , or R 411each independently represent (1) a hydrogen atom, (2) a C1-6 alkyl group, (3) a C2-6 acyl group, or (4) a C1-6 alkylsulfonyl group, m represents an integer of 0 to 2, n represents an integer of 0 to 5, and p represents an integer of 0 to 5.), or a pharmaceutically acceptable salt thereof; [2] a pharmaceutical composition comprising, as an active ingredient, the compound according to [1] above or a pharmaceutically acceptable salt thereof, and further comprising a pharmaceutically acceptable carrier; [3] a pharmaceutical composition according to [2] above which is an ABHD6 inhibitor, etc.

[0012] The compound of the present disclosure has inhibitory activity against ABHD6, has a low efflux ratio by P-glycoprotein, and is excellent in central distribution, and therefore can be used as an active ingredient in an agent for preventing and / or treating diseases associated with ABHD6.

[0013] The present disclosure will be described in detail below. In this specification, halogen atoms include fluorine, chlorine, bromine, and iodine atoms.

[0014] In this specification, C1-4 alkyl groups include methyl, ethyl, propyl, butyl groups, and isomers thereof, and C1-6 alkyl groups include methyl, ethyl, propyl, butyl, pentyl, hexyl groups, and isomers thereof.

[0015] In the present specification, C2-6 alkenyl groups include ethenyl, propenyl, butenyl, butadienyl, pentenyl, pentadienyl, hexenyl, hexadienyl groups, and isomers thereof.

[0016] In the present specification, C2-6 alkynyl groups include ethynyl, propynyl, butynyl, butadiynyl, pentynyl, pentadiynyl, hexynyl, hexadiynyl groups, and isomers thereof.

[0017] In this specification, C1-4 alkylene includes methylene, ethylene, propylene, butylene and isomers thereof.

[0018] In the present specification, the term "C1-6 haloalkyl group" means, for example, an alkyl group substituted by one or more halogen atoms, and specific examples include a fluoromethyl group, a chloromethyl group, a bromomethyl group, an iodomethyl group, a difluoromethyl group, a trifluoromethyl group, a 1-fluoroethyl group, a 2-fluoroethyl group, a 2-chloroethyl group, a pentafluoroethyl group, a 1-fluoropropyl group, a 2-chloropropyl group, a 3-fluoropropyl group, a 3-chloropropyl group, a 4,4,4-trifluorobutyl group, a 4-bromobutyl group, a 5,5,5-trifluoropentyl group, a 6,6,6-trifluorohexyl group, and isomers thereof.

[0019] In the present specification, the term "C2-6 haloalkenyl group" means, for example, an alkenyl group substituted by one or more halogen atoms, and specific examples include a 1-fluoroethenyl group, a 2-fluoroethenyl group, a 2-chloroethenyl group, a 1-fluoropropenyl group, a 2-chloropropenyl group, a 3-fluoropropenyl group, a 3-chloropropenyl group, a 4-bromobutenyl group, a 5,5,5-trifluoropentenyl group, a 6,6,6-trifluorohexenyl group, and isomers thereof.

[0020] In the present specification, the term "C2-6 haloalkynyl group" means, for example, an alkynyl group substituted by one or more halogen atoms, and specific examples include a 2-fluoroethynyl group, a 2-chloroethynyl group, a 3-fluoropropynyl group, a 3-chloropropynyl group, a 4-bromobutynyl group, a 5,5,5-trifluoropentynyl group, a 6,6,6-trifluorohexynyl group, and isomers thereof.

[0021] In this specification, C1-4 alkoxy groups include methoxy, ethoxy, propoxy, butoxy groups, and isomers thereof, and C1-6 alkoxy groups include methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy groups, and isomers thereof.

[0022] In the present specification, the term "C1-6 haloalkoxy group" means, for example, an alkoxy group substituted by one or more halogen atoms, and specific examples include a fluoromethoxy group, a chloromethoxy group, a bromomethoxy group, an iodomethoxy group, a difluoromethoxy group, a trifluoromethoxy group, a 1-fluoroethoxy group, a 2-fluoroethoxy group, a 2-chloroethoxy group, a pentafluoroethoxy group, a 1-fluoropropoxy group, a 2-chloropropoxy group, a 3-fluoropropoxy group, a 3-chloropropoxy group, a 4,4,4-trifluorobutoxy group, a 4-bromobutoxy group, a 5,5,5-trifluoropentyloxy group, a 6,6,6-trifluorohexyloxy group, and isomers thereof.

[0023] In the present specification, C1-6 alkylthio groups include methylthio, ethylthio, propylthio, butylthio, pentylthio, hexylthio groups, and isomers thereof.

[0024] In the present specification, C1-6 alkylsulfinyl groups include methylsulfinyl, ethylsulfinyl, propylsulfinyl, butylsulfinyl, pentylsulfinyl, hexylsulfinyl groups, and isomers thereof.

[0025] In the present specification, C1-6 alkylsulfonyl groups include methylsulfonyl, ethylsulfonyl, propylsulfonyl, butylsulfonyl, pentylsulfonyl, hexylsulfonyl groups, and isomers thereof.

[0026] In the present specification, C3-6 cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl groups.

[0027] In the present specification, C2-6 acyl includes ethanoyl, propanoyl, butanoyl, pentanoyl, hexanoyl and isomers thereof.

[0028] In the present specification, the term "3- to 6-membered cyclic group" refers to a C3-6 carbocyclic ring or a 3- to 6-membered heterocyclic ring. In the present specification, examples of the C3-6 carbocyclic ring include cyclopropane, cyclobutane, cyclopentane, cyclohexane, cyclobutene, cyclopentene, cyclohexene, cyclobutadiene, cyclopentadiene, cyclohexadiene, and a benzene ring.In the present specification, examples of the 3- to 6-membered heterocycle include aziridine, azetidine, oxirane, oxetane, thiirane, thietane, pyrrole, imidazole, triazole, tetrazole, pyrazole, pyridine, pyrazine, pyrimidine, pyridazine, furan, pyran, thiophene, thiopyran, oxazole, isoxazole, thiazole, isothiazole, furazan, oxadiazole, oxazine, oxadiazine, thiadiazole, thiazine, thiadiazine, pyrroline, pyrrolidine, imidazoline, imidazolidine, triazoline, triazolidine, tetrazoline, tetrazolidine, pyrazoline, pyrazolidine, dihydropyridine, tetrahydropyridine, piperidine, dihydropyrazine, tetrahydropyrazine, piperazine, dihydropyrimidine, tetrahydropyrimidine, perhydropyrimidine, dihydropyridazine, tetrahydropyridazine, perhydropyridazine, dihydrofuran, tetrahydrofuran, dihydropyran, tetrahydropyridine, Examples of the ring include lan, dihydrothiophene, tetrahydrothiophene, dihydrothiopyran, tetrahydrothiopyran, dihydrooxazole, tetrahydrooxazole (oxazolidine), dihydroisoxazole, tetrahydroisoxazole (isoxazolidine), dihydrothiazole, tetrahydrothiazole (thiazolidine), dihydroisothiazole, tetrahydroisothiazole (isothiazolidine), dihydrofurazan, tetrahydrofurazan, dihydrooxadiazole, tetrahydrooxadiazole (oxadiazolidine), dihydrooxazine, tetrahydrooxazine, dihydrooxadiazine, tetrahydrooxadiazine, dihydrothiadiazole, tetrahydrothiadiazole (thiadiazolidine), dihydrothiazine, tetrahydrothiazine, dihydrothiadiazine, tetrahydrothiadiazine, morpholine, thiomorpholine, oxathiane, dioxolane, dioxane, dithiolane, and dithiane rings.

[0029] In the present specification, the term "3-10 membered cyclic group" refers to a C3-10 carbocyclic ring and a 3-10 membered heterocyclic ring. Examples of the C3-10 carbocyclic ring in the present specification include cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, cyclononane, cyclodecane, cyclobutene, cyclopentene, cyclohexene, cycloheptene, cyclooctene, cyclononene, cyclodecene, cyclobutadiene, cyclopentadiene, cyclohexadiene, cycloheptadiene, cyclooctadiene, benzene, pentalene, perhydropentalene, azulene, perhydroazulene, indene, and perhydroisopropyl. indene, indane, naphthalene, dihydronaphthalene, tetrahydronaphthalene, perhydronaphthalene, bicyclo[1.1.1]pentane, bicyclo[2.1.1]hexane, bicyclo[2.1.1]hexene, bicyclo[2.2.1]heptane, bicyclo[2.2.1]heptene, bicyclo[3.1.1]heptane, bicyclo[3.1.1]heptene, bicyclo[2.2.2]octane, bicyclo[2.2.2]octene, bicyclo[3.2.1]octane and bicyclo[3.2.1]octene rings. In the present specification, examples of the 3- to 10-membered heterocycle include the above-mentioned 3- to 6-membered heterocycle, as well as azepine, diazepine, oxepin, thiepine, oxazepine, oxadiazepine, thiazepine, thiadiazepine, indole, isoindole, indolizine, benzofuran, isobenzofuran, benzothiophene, isobenzothiophene, dithianaphthalene, indazole, quinoline, isoquinoline, quinolizine, purine, phthalazine, pteridine, naphthyridine, quinoxaline, quinazoline, cinnoline, benzoxazole, benzothiazoline, and the like. benzols, benzimidazoles, chromenes, benzofurazans, benzothiadiazoles, benzotriazoles, dihydroazepines, tetrahydroazepines, perhydroazepines, dihydrodiazepines, tetrahydrodiazepines, perhydrodiazepines, dihydrooxepines, tetrahydrooxepines, perhydrooxepines, dihydrothiepines, tetrahydrothiepines, perhydrothiepines, dihydrooxazepines, tetrahydrooxazepines, perhydrooxazepines, dihydrooxadiazepines, tetrahydrooxadiazepines,Perhydrooxadiazepine, dihydrothiazepine, tetrahydrothiazepine, perhydrothiazepine, dihydrothiadiazepine, tetrahydrothiadiazepine, perhydrothiadiazepine, indoline, isoindoline, dihydrobenzofuran, perhydrobenzofuran, dihydroisobenzofuran, perhydroisobenzofuran, dihydrobenzothiophene, perhydrobenzothiophene, dihydroisobenzothiophene, perhydroisobenzothiophene, dihydroindazole, perhydroindazole, dihydroquinoline, tetrahydro Quinoline, perhydroquinoline, dihydroisoquinoline, tetrahydroisoquinoline, perhydroisoquinoline, dihydrophthalazine, tetrahydrophthalazine, perhydrophthalazine, dihydronaphthyridine, tetrahydronaphthyridine, perhydronaphthyridine, dihydroquinoxaline, tetrahydroquinoxaline, perhydroquinoxaline, dihydroquinazoline, tetrahydroquinazoline, perhydroquinazoline, dihydrocinnoline, tetrahydrocinnoline, perhydrocinnoline, benzoxathiane, dihydrobenzoxazine, Dihydrobenzothiazine, pyrazinomorpholine, dihydrobenzoxazole, perhydrobenzoxazole, dihydrobenzothiazole, perhydrobenzothiazole, dihydrobenzimidazole, perhydrobenzimidazole, dioxaindane, benzodioxane, chroman, benzodithiolane, benzodithiane, azaspiro[4.4]nonane, oxazaspiro[4.4]nonane, dioxaspiro[4.4]nonane, azaspiro[4.5]decane, thiaspiro[4.5]decane, dithiaspiro[4.5]decane, dioxaspiro[4. 5]decane, oxazaspiro[4.5]decane, azabicyclo[3.2.1]octane, oxabicyclo[3.2.1]octane, thieno[3,2-c]pyrazole, thieno[2,3-c]pyrazole, thieno[2,3-d]thiazole, thieno[2,3-d][1.2.3]triazole, dihydropyrano[3,4-d]thiazole, dihydrothieno[2,3-b]pyran, dihydrothieno[3,2-c]pyran, dihydrothieno[3,2-b]pyran, dihydrothieno[3,2-c]thiopyran, tetrahydrothieno[3,2-b]pyridine,Examples thereof include tetrahydrothieno[3,2-c]pyridine, thieno[3,2-c]pyridine, thieno[3,2-c]pyran, tetrahydrothieno[2,3-c]pyridine, pyrazolo[5,1-b][1,3]thiazole, 1,3-benzothiazole, thieno[3,2-b]furan, dihydro[1,3]thiazolo[4,5-c]pyridine, dihydrothieno[2,3-c]pyridine, and tetrahydrothieno[2,3-d]oxepine ring.

[0030] In the present specification, the term "3-15-membered cyclic group" refers to a C3-15 carbocyclic ring or a 3-15-membered heterocyclic ring. In the present specification, examples of the C3-15 carbocyclic ring include the above-mentioned C3-10 carbocyclic ring, as well as heptalene, biphenylene, as-indacene, s-indacene, acenaphthylene, acenaphthene, fluorene, phenalene, phenanthrene, and anthracene rings. In the present specification, examples of the 3-15 membered heterocycle include the above-mentioned 3-10 membered heterocycle, as well as benzoxadiazepine, benzothiadiazepine, benzoxazepine, benzothiazepine, benzodiazepine, dihydrobenzodiazepine, tetrahydrobenzodiazepine, benzodioxepane, dihydrobenzoxazepine, tetrahydrobenzoxazepine, benzoxepine, benzothiepine, benzazepine, dihydrobenzazepine, tetrahydrobenzazepine, perimidine, β-carboline, dihydrocarbazole Examples of suitable alkyl groups include tetrahydrocarbazole, dihydrodibenzofuran, dihydrodibenzothiophene, tetrahydrodibenzofuran, tetrahydrodibenzothiophene, carbazole, dibenzofuran, dibenzothiophene, phenothiazine, phenoxazine, phenoxathiin, thianthrene, phenazine, phenanthroline, xanthene, dihydroacridine, tetrahydroacridine, acridine, phenanthridine, and dihydropyrrolo[1,2-b]thieno[2,3-d]pyrazole rings.

[0031] In the present specification, the term "5-6 membered cyclic group" refers to a C5-6 carbocyclic ring or a C5-6 membered heterocyclic ring. In the present specification, examples of the C5-6 carbocyclic ring include cyclopentane, cyclohexane, cyclopentene, cyclohexene, cyclopentadiene, cyclohexadiene, and a benzene ring.

[0033] In the present specification, examples of the 5- or 6-membered heterocycle include pyrrole, imidazole, triazole, tetrazole, pyrazole, pyridine, pyrazine, pyrimidine, pyridazine, furan, pyran, thiophene, thiopyran, oxazole, isoxazole, thiazole, isothiazole, furazan, oxadiazole, oxazine, oxadiazine, thiadiazole, thiazine, thiadiazine, pyrroline, pyrrolidine, imidazoline, imidazolidine, triazoline, triazolidine, tetrazoline, tetrazolidine, pyrazoline, pyrazolidine, dihydropyridine, tetrahydropyridine, piperidine, dihydropyrazine, tetrahydropyrazine, piperazine, dihydropyrimidine, tetrahydropyrimidine, perhydropyrimidine, dihydropyridazine, tetrahydropyridazine, perhydropyridazine, dihydrofuran, tetrahydrofuran, dihydropyran, tetrahydropyran, dihydrothiophene, tetrahydrofuran, tetrahydrofuran, dihydropyran, dihydrothiophene, tetrahydrofuran, tetrahydrofuran, dihydrothiophene, tetrahydrofuran, dihydrofuran, dihydrothiophene, tetrahydrofuran, dihydrofuran, dihydrothiophene, tetrahydrofuran, dihydrofuran, dihydrothiophene, di ... Examples of the dihydrothiophene include dihydrothiopyran, dihydrothiopyran, dihydrooxazole, tetrahydrooxazole (oxazolidine), dihydroisoxazole, tetrahydroisoxazole (isoxazolidine), dihydrothiazole, tetrahydrothiazole (thiazolidine), dihydroisothiazole, tetrahydroisothiazole (isothiazolidine), dihydrofurazan, tetrahydrofurazan, dihydrooxadiazole, tetrahydrooxadiazole (oxadiazolidine), dihydrooxazine, tetrahydrooxazine, dihydrooxadiazine, tetrahydrooxadiazine, dihydrothiadiazole, tetrahydrothiadiazole (thiadiazolidine), dihydrothiazine, tetrahydrothiazine, dihydrothiadiazine, tetrahydrothiadiazine, morpholine, thiomorpholine, oxathiane, dioxolane, dioxane, dithiolane, and dithiane rings.

[0032] In the present specification, the phrase "one to two carbon atoms may be replaced by an oxygen atom or an optionally oxidized sulfur atom" means that one or two carbon atoms (-CH) in structurally possible positions in the substituent may be replaced by an oxygen atom or an optionally oxidized sulfur atom. 2 -) is an oxygen atom (-O-) or an optionally oxidized sulfur atom (-S-, -SO-, or -SO 2 -), and specifically, in the case of a C1-6 alkyl group, for example, 3 -O-CH 2 - group, CH 3 -CH 2 -O-CH 2 - group, CH 3 -O-CH 2 -CH 2 - group, CH 3 -O-CH 2 -CH 2 -CH 2 - group and CH 3 -CH 2 -O-CH 2 -CH 2 In the present specification, the phrase "one to two carbon atoms may be replaced by a nitrogen atom or an optionally oxidized sulfur atom" means that one or two carbon atoms (-CH 2 -) is a nitrogen atom (-NH- or -N=) or an optionally oxidized sulfur atom (-S-, -SO-, or -SO 2 -), and specifically, in the case of a C1-6 alkyl group, for example, 3 -NH-CH 2 - group, CH 3 -CH 2 -NH-CH 2 - group, CH 3 -NH-CH 2 -CH 2 - group, CH 3 -NH-CH 2 -CH 2 -CH 2 - group and CH 3 -CH 2 -NH-CH 2 -CH 2 - group and the like.

[0033] In this specification, "two R 2 represents a C alkyl group, a C alkenyl group, a C alkynyl group, a C alkoxy group, a C haloalkyl group, a C haloalkenyl group, a C haloalkynyl group, or a C haloalkoxy group, and may form a 5- or 6-membered cyclic group together with the carbon atom to which it is bonded" refers to a partial structure of the following general formula (I): (wherein all symbols have the same meanings as above), R 2 represents (1) a halogen atom, (2) a C1-6 alkyl group, (3) a C2-6 alkenyl group, (4) a C2-6 alkynyl group, (5) a C1-6 alkoxy group, (6) a C1-6 haloalkyl group, (7) a C2-6 haloalkenyl group, (8) a C2-6 haloalkynyl group, or (9) a C1-6 haloalkoxy group, and 1 to 2 carbon atoms in the C1-6 alkyl group, C2-6 alkenyl group, C2-6 alkynyl group, C1-6 alkoxy group, C1-6 haloalkyl group, C2-6 haloalkenyl group, C2-6 haloalkynyl group, or C1-6 haloalkoxy group may be replaced by a nitrogen atom or an optionally oxidized sulfur atom, when two R 2 together with the carbon atom to which it is attached to form a 5- or 6-membered cyclic group, such as This means forming a 9-membered or 10-membered cyclic group such as:

[0034] In this disclosure, R 3 may substitute for any hydrogen atom in hexahydrocyclopenta[c]pyrrole. 1 is preferably a chlorine atom or a bromine atom. 2 is preferably a C1-6 alkyl group, a C1-6 alkoxy group, a C1-6 haloalkyl group, or a C1-6 haloalkoxy group, and more preferably a methoxy group or a trifluoromethyl group. 3 is preferably a halogen atom, a C1-6 alkyl group, a C1-6 alkoxy group, or a hydroxyl group, and more preferably a fluorine atom or a methyl group.

[0035] In the present disclosure, ring1 is preferably a 3- to 10-membered cyclic group, more preferably (In the formula, * indicates the bonding position with the carbonyl group, and the hydrogen atom represented by NH is R 4 and more preferably (In the formula, * indicates the bonding position with the carbonyl group, and the hydrogen atom represented by NH is R 4 and wherein R is a ring structure selected from the group consisting of:

[0036] In this disclosure, R 4 is preferably a halogen atom, a C1-6 alkyl group, a C1-6 alkoxy group, a C1-6 haloalkyl group, a C1-6 haloalkoxy group, a 3- to 6-membered cyclic group, or —COOR 403 or a cyano group, and more preferably a fluorine atom, a C1-6 alkyl group, a C1-6 alkoxy group, a C1-6 haloalkyl group, a C1-6 haloalkoxy group, a cyclopropyl group, a benzene ring, a pyridine ring, or —COOCH 3 , —COOtBu, or a cyano group, and more preferably a methyl group, a difluoromethyl group, a 2-fluoroethoxy group, or a cyclopropyl group.

[0037] In the present disclosure, m is preferably 0 or 1. In the present disclosure, n is preferably 0, 1, or 2. In the present disclosure, p is preferably 0, 1, or 2.

[0038] In the present disclosure, the compound represented by general formula (I) is preferably a compound represented by general formula (I-1): (In the formula, R 2-1 represents (1) a C1-6 alkyl group, (2) a C1-6 alkoxy group, (3) a C1-6 haloalkyl group, or (4) a C1-6 haloalkoxy group; R 4-1 is (1) a halogen atom, (2) a C1-6 alkyl group, (3) a C1-6 alkoxy group, (4) a C1-6 haloalkyl group, (5) a C1-6 haloalkoxy group, (6) a cyclopropyl group, (7) a benzene ring, (8) a pyridine ring, or (9) -COOCH 3, (10) -COOtBu, or (11) a cyano group, and ring1-1 represents the following ring structure: (In the formula, * indicates the bonding position with the carbonyl group, and the hydrogen atom represented by NH is R 4-1 The other symbols have the same meanings as the above symbols.)

[0039] In the present disclosure, the compound represented by general formula (I) is preferably a compound represented by the above-mentioned R 1 , R 2 , R 3 , R 4 , ring1, n, m, and p are each a combination of preferred definitions.

[0040] In the present disclosure, another embodiment of the compound represented by general formula (I) is most preferably the example compound described in the Examples below, or a pharmaceutically acceptable salt thereof. In the present disclosure, all isomers are encompassed unless otherwise specified. For example, alkyl groups, alkoxy groups, and alkylene groups include both straight-chain and branched-chain isomers. Furthermore, isomers (E, Z, cis, trans) at double bonds, rings, and fused rings, isomers due to the presence of asymmetric carbons (R, S, α, β, enantiomers, diastereomers), optically active isomers with optical rotation (D, L, d, l), polar isomers (high polarity, low polarity) obtained by chromatographic separation, equilibrium compounds, rotational isomers, mixtures of these in any proportion, and racemic mixtures are all encompassed in the present disclosure. In addition, all isomers due to tautomerism are also encompassed in the present disclosure.

[0041] In this disclosure, unless otherwise specified, symbols that will be apparent to those skilled in the art are used. represents bonding beyond the plane of the paper (i.e., α-configuration), indicates that the bond is on the front side of the paper (i.e., β-configuration), represents an arbitrary mixture of α- and β-configurations.

[0042] [Salts] The compound represented by general formula (I) can be converted into a salt by a known method. The salt is a pharmaceutically acceptable salt. Preferably, the salt is water-soluble. Examples of pharmaceutically acceptable salts include acid addition salts, alkali metal salts, alkaline earth metal salts, ammonium salts, and amine salts. Examples of acid addition salts include inorganic acid salts such as hydrochloride, hydrobromide, hydroiodide, sulfate, phosphate, and nitrate, and organic acid salts such as acetate, lactate, tartrate, benzoate, citrate, methanesulfonate, ethanesulfonate, trifluoroacetate, benzenesulfonate, toluenesulfonate, isethionate, glucuronate, and gluconate. Examples of alkali metal salts include potassium salts and sodium salts. Examples of alkaline earth metal salts include calcium salts and magnesium salts. Examples of ammonium salts include tetramethylammonium salts. Examples of amine salts include triethylamine salts, methylamine salts, dimethylamine salts, cyclopentylamine salts, benzylamine salts, phenethylamine salts, piperidine salts, monoethanolamine salts, diethanolamine salts, tris(hydroxymethyl)aminomethane salts, lysine salts, arginine salts, and N-methyl-D-glucamine salts.

[0043] The compounds of the present disclosure can be converted into N-oxides by any method. N-oxides refer to compounds in which the nitrogen atom of the compound represented by formula (I) is oxidized.

[0044] The compound represented by general formula (I) and its pharmaceutically acceptable salts may exist in a non-solvated form or in a solvated form with a pharmaceutically acceptable solvent such as water or ethanol. The solvate is preferably a hydrate. The compound represented by general formula (I) and its pharmaceutically acceptable salts may be converted into a solvate.

[0045] The compound of formula (I) can form a co-crystal with a suitable co-crystal former. The co-crystal is preferably a pharmaceutically acceptable co-crystal former. A co-crystal is typically defined as a crystal formed by two or more different molecules through intermolecular interactions other than ionic bonding. A co-crystal may also be a complex of a neutral molecule and a salt. Co-crystals can be prepared by known methods, such as melt crystallization, recrystallization from a solvent, or by physically grinding the components together. Suitable co-crystal formers include those described in WO 2006 / 007448.

[0046] In this disclosure, all references to the disclosed compounds include a compound represented by general formula (I), a pharmaceutically acceptable salt thereof, an N-oxide thereof, a solvate (e.g., hydrate) thereof, or a co-crystal thereof, or an N-oxide of a pharmaceutically acceptable salt of a compound represented by general formula (I), a solvate (e.g., hydrate) thereof, or a co-crystal thereof.

[0047] [Prodrug] A prodrug of the compound represented by formula (I) refers to a compound that is converted into the compound represented by formula (I) in vivo by a reaction catalyzed by an enzyme, gastric acid, or the like. Examples of the prodrug of the compound represented by general formula (I) include, when the compound represented by general formula (I) has an amino group, compounds in which the amino group has been acylated, alkylated or phosphorylated (for example, compounds in which the amino group of the compound represented by general formula (I) has been eicosanoylated, alanylated, pentylaminocarbonylated, (5-methyl-2-oxo-1,3-dioxolen-4-yl)methoxycarbonylated, tetrahydrofuranylated, pyrrolidylmethylated, pivaloyloxymethylated, acetoxymethylated or tert-butylated); when the compound represented by general formula (I) has a hydroxyl group, compounds in which the hydroxyl group has been acylated, alkylated, phosphorylated or borated (for example, compounds in which the hydroxyl group of the compound represented by general formula (I) has been acetylated, palmitoylated or propanoylated). , pivaloylated, succinylated, fumarylated, alanylated, dimethylaminomethylcarbonylated compounds, etc.); when the compound represented by general formula (I) has a carboxyl group, compounds in which the carboxyl group has been esterified or amidated (for example, compounds in which the carboxyl group of the compound represented by general formula (I) has been ethyl-esterified, phenyl-esterified, carboxymethyl-esterified, dimethylaminomethyl-esterified, pivaloyloxymethyl-esterified, 1-{(ethoxycarbonyl)oxy}ethyl-esterified, phthalidyl-esterified, (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl-esterified, 1-{[(cyclohexyloxy)carbonyl]oxy}ethyl-esterified, methylamidated compounds, etc.). These compounds can be produced by known methods. Furthermore, the prodrug of the compound represented by general formula (I) may be any of a hydrate, a solvate, and a non-hydrate. Furthermore, the prodrug of the compound represented by general formula (I) may be one that is converted into the compound represented by general formula (I) under physiological conditions, as described in "Drug Development," Vol. 7, "Molecular Design," pp. 163-198, Hirokawa Publishing, 1990.

[0048] Furthermore, each atom constituting the compound represented by general formula (I) may contain its isotope (e.g., 2 H. 3 H. 11 C. 13 C. 14 C. 15 N. 16 N. 17 O. 18 O. 18 F. 35 S. 36 Cl, 77 Br, 125 In one embodiment, the compound represented by general formula (I) is a compound, a salt thereof, or a solvate thereof, in which one or more atoms are radioactive isotopes of said atoms. The radioactive isotope is 15 O. 13 N. 11 C, and 18 Preferably, the radioisotope is selected from the group consisting of, but not limited to, F. 11 C or 18 F. More preferably, the radioisotope is 18 F. Preferably, the C1-6 haloalkoxy group bound to ring 1 is a group containing a radioisotope. More preferably, the 2-fluoroethoxy group is a group containing a radioisotope. The compound represented by general formula (I) containing a radioisotope is preferably a compound represented by the formula [ 18 F]-[(3aS,4R,6aR)-4-[(6-bromo-3-pyridazinyl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl][5-(2-fluoroethoxy)-2-thienyl]methanone.

[0049] [Method for Producing Compounds of the Present Disclosure] The compounds of the present disclosure can be produced by appropriately modifying and combining known methods, such as the methods shown below, methods similar thereto, the method described in Comprehensive Organic Transformations: A Guide to Functional Group Preparations, 3rd Edition (Richard C. Larock, John Wiley & Sons Inc., 2018), or the methods shown in the Examples. A salt may be used as the starting material. The order of carrying out each reaction can be appropriately changed depending on the protecting groups introduced and the reaction conditions.

[0050] Furthermore, compounds having an amino group, a carboxyl group, or a hydroxyl group can be produced, if necessary, by using a compound protected with a protecting group commonly used for these groups, for example, a protecting group described in T. W. Greene, Protective Groups in Organic Synthesis, Wiley, New York, 5th Edition, 2014, and then carrying out a known deprotection reaction after an appropriate reaction step. Examples of protecting groups for carboxyl groups include methyl, ethyl, tert-butyl, trichloroethyl, benzyl (Bn), phenacyl, p-methoxybenzyl, trityl, and 2-chlorotrityl. Examples of protecting groups for amino groups or tetrazolyl groups include benzyloxycarbonyl groups, tert-butoxycarbonyl groups, allyloxycarbonyl (Alloc) groups, 1-methyl-1-(4-biphenyl)ethoxycarbonyl (Bpoc) groups, trifluoroacetyl groups, 9-fluorenylmethoxycarbonyl groups, benzyl (Bn) groups, p-methoxybenzyl groups, benzyloxymethyl (BOM) groups, and 2-(trimethylsilyl)ethoxymethyl (SEM) groups. Examples of the protecting group for a hydroxyl group or hydroxamic acid include methyl, trityl, methoxymethyl (MOM), 1-ethoxyethyl (EE), methoxyethoxymethyl (MEM), 2-tetrahydropyranyl (THP), trimethylsilyl (TMS), triethylsilyl (TES), tert-butyldimethylsilyl (TBDMS), tert-butyldiphenylsilyl (TBDPS), acetyl (Ac), pivaloyl, benzoyl, benzyl (Bn), p-methoxybenzyl, allyloxycarbonyl (Alloc), 2,2,2-trichloroethoxycarbonyl (Troc), and the like.

[0051] Deprotection reactions are known and can be carried out by the following methods. Examples include: (1) deprotection reaction by alkaline hydrolysis, (2) deprotection reaction under acidic conditions, (3) deprotection reaction by hydrogenolysis, (4) deprotection reaction of a silyl group, (5) deprotection reaction using a metal, and (6) deprotection reaction using a metal complex. These methods are described in detail below. (1) Deprotection reaction by alkaline hydrolysis is carried out, for example, in an organic solvent (e.g., methanol, tetrahydrofuran (hereinafter, THF), dioxane, etc.) using an alkali metal hydroxide (e.g., sodium hydroxide, potassium hydroxide, lithium hydroxide, etc.), an alkaline earth metal hydroxide (e.g., barium hydroxide, calcium hydroxide, etc.) or a carbonate (e.g., sodium carbonate, potassium carbonate, etc.), or an aqueous solution thereof, or a mixture thereof, at 0 to 40°C. (2) The deprotection reaction under acidic conditions is carried out, for example, in an organic solvent (e.g., dichloromethane, chloroform, dioxane, ethyl acetate, methanol, isopropyl alcohol, THF, anisole, etc.), in an organic acid (e.g., acetic acid, trifluoroacetic acid, methanesulfonic acid, p-tosylic acid, etc.), an inorganic acid (e.g., hydrochloric acid, sulfuric acid, etc.), or a mixture thereof (e.g., hydrogen bromide / acetic acid, etc.), in the presence or absence of 2,2,2-trifluoroethanol, at 0 to 100°C. (3) The deprotection reaction by hydrogenolysis is carried out, for example, in a solvent (e.g., an ether (e.g., THF, dioxane, dimethoxyethane, diethyl ether, etc.), an alcohol (e.g., methanol, ethanol, etc.), a benzene (e.g., benzene, toluene, etc.), a ketone (e.g., acetone, methyl ethyl ketone, etc.), a nitrile (e.g., acetonitrile, etc.), an amide (e.g., N,N-dimethylformamide (DMF), etc.), water, ethyl acetate, acetic acid, or a mixed solvent of two or more thereof, etc.) in the presence of a catalyst (e.g., palladium-carbon, palladium black, palladium hydroxide-carbon, platinum oxide, Raney nickel, etc.) under a hydrogen atmosphere at normal or elevated pressure or in the presence of ammonium formate, at 0 to 200°C. (4) The deprotection reaction of a silyl group is carried out, for example, in a water-miscible organic solvent (e.g., THF, acetonitrile, etc.) using tetrabutylammonium fluoride at 0 to 40°C.Alternatively, the reaction is carried out in, for example, an organic acid (e.g., acetic acid, trifluoroacetic acid, methanesulfonic acid, p-tosylic acid, etc.), an inorganic acid (e.g., hydrochloric acid, sulfuric acid, etc.), or a mixture thereof (e.g., hydrogen bromide / acetic acid, etc.) at −10 to 100° C. (5) The deprotection reaction using a metal is carried out in, for example, an acidic solvent (e.g., acetic acid, a buffer solution of pH 4.2 to 7.2, or a mixture of such a solution with an organic solvent such as THF) in the presence of zinc powder at 0 to 40° C., if necessary, with ultrasonication. (6) The deprotection reaction using a metal complex is carried out, for example, in an organic solvent (e.g., dichloromethane, DMF, THF, ethyl acetate, acetonitrile, dioxane, ethanol, or the like), water, or a mixed solvent thereof, in the presence of a trapping reagent (e.g., tributyltin hydride, triethylsilane, dimedone, morpholine, diethylamine, pyrrolidine, or the like), an organic acid (e.g., acetic acid, formic acid, 2-ethylhexanoic acid, or the like) and / or an organic acid salt (e.g., sodium 2-ethylhexanoate, potassium 2-ethylhexanoate, or the like), in the presence or absence of a phosphine reagent (e.g., triphenylphosphine, or the like), using a metal complex (e.g., tetrakistriphenylphosphinepalladium(0), bis(triphenylphosphine)palladium(II) dichloride, palladium(II) acetate, tris(triphenylphosphine)rhodium(I) chloride, or the like), at 0 to 40°C.

[0052] The compound of formula (I) can be prepared by reaction scheme 1. (In Reaction Scheme 1, PG represents an amino-protecting group, Y represents a halogen atom, and the other symbols have the same meanings as above.)

[0053] In Reaction Scheme 1, Reaction 1-1 is a halogen substitution reaction or a cross-coupling reaction. The halogen substitution reaction is known and can be carried out, for example, in an organic solvent (DMF, dimethyl sulfoxide, chloroform, dichloromethane, diethyl ether, THF, methyl t-butyl ether, etc.) in the presence of a base (sodium ethylate, sodium hydroxide, potassium hydroxide, triethylamine, diisopropylethylamine, sodium carbonate, sodium hydrogencarbonate, potassium carbonate, cesium carbonate, tripotassium phosphate, cesium fluoride, barium hydroxide, tetrabutylammonium fluoride, etc.) or an aqueous solution thereof, or a mixture thereof, at 0 to 200°C. Cross-coupling reactions are known. For example, a cross-coupling reaction can be carried out in an organic solvent (benzene, toluene, DMF, dioxane, THF, methanol, acetonitrile, dimethoxyethane, acetone, etc.) using a base (sodium ethylate, sodium hydroxide, potassium hydroxide, triethylamine, sodium carbonate, sodium bicarbonate, potassium carbonate, cesium carbonate, thallium carbonate, tripotassium phosphate, cesium fluoride, barium hydroxide, tetrabutylammonium fluoride, etc.) or an aqueous solution thereof, or a mixture thereof, and a catalyst (tetrakis(triphenylphosphine)palladium (Pd(PPh 3 ) 4 ), bis(triphenylphosphine)palladium dichloride (PdCl 2 (PPh 3 ) 2 ), palladium acetate (Pd(OAc) 2 ), palladium black, 1,1'-bis(diphenylphosphinoferrocene)dichloropalladium (PdCl 2 (dppf) 2 ), diallylpalladium dichloride (PdCl 2 (allyl) 2 ), phenylbis(triphenylphosphine)palladium iodide (PhPdI(PPh 3 ) 2 The reaction is carried out by reacting the compound at room temperature to 120° C. in the presence of a solvent such as methyl methyl acrylate.

[0054] In reaction scheme 1, reaction 1-2 is a deprotection reaction, which can be carried out in the same manner as described above.

[0055] In Reaction Scheme 1, Reactions 1-3 are amidation reactions. Amidation reactions are known, and examples thereof include: (1) a method using an acid halide; (2) a method using a mixed acid anhydride; and (3) a method using a condensing agent. Specific examples of these methods include: (1) a method using an acid halide, which involves reacting a carboxylic acid with an acid halide-forming agent (oxalyl chloride, thionyl chloride, etc.) in an organic solvent (chloroform, dichloromethane, diethyl ether, THF, etc.) or without a solvent at a temperature of −20° C. to reflux, and then reacting the resulting acid halide with an amine in an organic solvent (chloroform, dichloromethane, diethyl ether, THF, etc.) in the presence of a base (pyridine, triethylamine, dimethylaniline, dimethylaminopyridine, diisopropylethylamine, etc.) at a temperature of 0 to 40° C. Alternatively, the resulting acid halide can be reacted with an amine in an organic solvent (dioxane, THF, etc.) using an alkaline aqueous solution (such as aqueous sodium bicarbonate or sodium hydroxide solution) at 0 to 40° C. (2) A method using a mixed acid anhydride can be carried out by, for example, reacting a carboxylic acid with an acid halide (such as pivaloyl chloride, tosyl chloride, mesyl chloride, etc.) or an acid derivative (such as ethyl chloroformate or isobutyl chloroformate) in the presence of a base (such as pyridine, triethylamine, dimethylaniline, dimethylaminopyridine, or diisopropylethylamine) in an organic solvent (such as chloroform, dichloromethane, diethyl ether, or THF) at 0 to 40° C., and then reacting the resulting mixed acid anhydride with an amine in an organic solvent (such as chloroform, dichloromethane, diethyl ether, or THF) at 0 to 40° C.(3) The method using a condensing agent involves, for example, reacting a carboxylic acid and an amine in an organic solvent (chloroform, dichloromethane, DMF, diethyl ether, THF, etc.) or without a solvent, in the presence or absence of a base (pyridine, triethylamine, dimethylaniline, dimethylaminopyridine, etc.), with a condensing agent (1,3-dicyclohexylcarbodiimide (DCC), 1-ethyl-3-[3-(dimethylamino)propyl]carbodiimide (EDC), 1,1′-carbonyldiimidazole (CDI), 2-chloro-1-methylpyridinium iodide, 1-propylphosphonic acid cyclic anhydride (1-propanephosphonic acid cyclic anhydride, etc.)). anhydride, PPA, etc.), O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU), in the presence or absence of 1-hydroxybenztriazole (HOBt), at 0 to 40°C.

[0056] It is desirable that the reactions (1), (2) and (3) are all carried out under an inert gas (argon, nitrogen, etc.) atmosphere and under anhydrous conditions.

[0057] Compounds of general formula 1a can be prepared according to reaction scheme 2. (In Reaction Scheme 2, all symbols have the same meaning as above.) In Reaction Scheme 2, Reaction 2-1 is a cyclization reaction, which is carried out, for example, in an organic solvent (DMF, dimethyl sulfoxide, chloroform, dichloromethane, diethyl ether, THF, methyl t-butyl ether, etc.) in the presence of an acid (trifluoroacetic acid, etc.) at a temperature of 0 to 100° C. In Reaction Scheme 2, Reaction 2-2 is a reduction reaction of a carbonyl group, which is carried out in an organic solvent (dichloroethane, dichloromethane, DMF, THF, a mixture thereof, etc.) in the presence of a reducing agent (sodium borohydride, etc.) at a temperature of 0 to 40° C.

[0058] Among the compounds represented by general formula (I), 18 The compound F was prepared by reacting a precursor having a leaving group with Kryptofix 2.2.2 (CAS number: 23978-09-8) in the presence or absence of [ 18F] potassium fluoride, etc.

[0059] In each reaction in the present specification, the compounds represented by general formula 1b, general formula 1e, general formula 2a, and general formula 2b, which are used as starting materials, are either known or can be easily produced by a combination of known methods, such as the methods described in Comprehensive Organic Transformations: A Guide to Functional Group Preparations, 3rd Edition (Richard C. Larock, John Wiley & Sons Inc., 2018), or methods in which known methods are partially modified.

[0060] Among the compounds disclosed herein, optically active compounds can be produced using optically active starting materials or reagents, or by optically resolving a racemic production intermediate and then leading to the compound disclosed herein, or by optically resolving a racemic compound disclosed herein.

[0061] This optical resolution is well known, and examples thereof include a method in which a salt or complex is formed with another optically active compound, and the target compound is then isolated after recrystallization, or directly separated using a chiral column or the like.

[0062] In each reaction herein, reactions involving heating can be carried out using a water bath, oil bath, sand bath or microwave, as will be apparent to those skilled in the art.

[0063] In each reaction herein, a solid-phase-supported reagent supported on a high molecular weight polymer (for example, polystyrene, polyacrylamide, polypropylene, polyethylene glycol, etc.) may be used as appropriate.

[0064] In each reaction in this specification, the reaction product can be purified by a conventional purification method, for example, distillation under atmospheric pressure or reduced pressure, high performance liquid chromatography using silica gel or magnesium silicate, thin layer chromatography, ion exchange resin, scavenger resin, or column chromatography, washing, recrystallization, etc. Purification may be carried out for each reaction or after completion of several reactions.

[0065] [Toxicity] The compounds of the present disclosure have low toxicity and can therefore be used safely as pharmaceuticals.

[0066] [Application to Pharmaceuticals] The compounds of the present disclosure have inhibitory activity against ABHD6 and are therefore useful as prophylactic and / or therapeutic agents for diseases associated with ABHD6, such as pain, neurological diseases, inflammatory diseases, autoimmune diseases, metabolic diseases, malignant tumors, etc.

[0067] More specifically, examples of pain include pain associated with osteoarthritis, cancer pain, pain associated with chemotherapy, chronic low back pain, low back pain associated with osteoporosis, pain from fractures, pain associated with rheumatoid arthritis, neuropathic pain, post-herpetic pain, pain associated with diabetic neuropathy, fibromyalgia, pain associated with pancreatitis, pain associated with interstitial cystitis / bladder pain syndrome, pain associated with endometriosis, pain associated with irritable bowel syndrome, migraine, and pain associated with dental pulpitis.

[0068] Examples of neurological diseases include tremor, dyskinesia, dystonia, spasticity, compulsive and obsessive behavior, depression, psychiatric disorders including anxiety disorders (e.g., panic disorder, acute stress reaction, post-traumatic stress disorder, obsessive-compulsive disorder, agoraphobia, social phobia), mood disorders, epilepsy, traumatic brain injury, spinal cord injury, multiple sclerosis, encephalomyelitis, Parkinson's disease, Huntington's chorea, Alzheimer's disease, and sleep disorders.

[0069] Examples of inflammatory diseases include arthritis, rheumatoid arthritis, osteoarthritis, spondylitis, gout, vasculitis, Crohn's disease, irritable bowel syndrome, etc. Examples of autoimmune diseases include psoriasis, amyotrophic lateral sclerosis (ALS), multiple sclerosis, Sjogren's syndrome, systemic lupus erythematosus, AIDS, etc.

[0070] Examples of metabolic diseases include obesity, metabolic syndrome, dyslipidemia, diabetes, and fatty liver.

[0071] Malignant tumors include, for example, breast cancer, ovarian cancer, colorectal cancer (e.g., colon cancer, etc.), lung cancer (e.g., non-small cell lung cancer, etc.), prostate cancer, head and neck cancer (e.g., oral squamous cell carcinoma, head and neck squamous cell carcinoma, pharyngeal cancer, laryngeal cancer, tongue cancer, thyroid cancer, acoustic neuroma, etc.), lymphoma (e.g., B-cell lymphoma, T-cell lymphoma, etc.), uveal malignant melanoma, thymoma, mesothelioma, esophageal cancer, gastric cancer, duodenal cancer, hepatocellular carcinoma, bile duct cancer, gallbladder cancer, pancreatic cancer, renal cell carcinoma, renal pelvis and ureter cancer, bladder cancer, penile cancer, testicular cancer, uterine cancer, vaginal cancer, vulvar cancer, skin cancer (e.g., malignant melanoma), malignant bone tumor, soft tissue sarcoma, chondrosarcoma, leukemia (e.g., acute myeloid leukemia, acute lymphocytic leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia), myelodysplastic syndrome, brain tumor, or multiple myeloma.

[0072] As used herein, the prevention and / or treatment of malignant tumors includes, for example, treatments performed to (a) reduce cancer cell proliferation, (b) reduce symptoms caused by cancer and improve the quality of life of cancer patients, (c) reduce the dose of other anticancer drugs or adjuvant cancer treatment drugs already administered, (d) suppress cancer progression, (e) suppress cancer recurrence, and / or (f) extend the survival time of cancer patients. Furthermore, "suppressing cancer progression" means delaying cancer progression, stabilizing cancer-related symptoms, and reversing the progression of symptoms. "Suppressing recurrence" means prophylactically preventing cancer recurrence in patients whose cancer lesions have completely or substantially disappeared or been removed by cancer treatment or surgical resection.

[0073] To use the disclosed compounds for the prevention and / or treatment of the above-mentioned diseases, the active ingredient is typically formulated with a pharmaceutically acceptable carrier, such as various additives or solvents, and then administered systemically or locally, orally or parenterally. Here, a pharmaceutically acceptable carrier refers to a substance other than the active ingredient that is generally used in pharmaceutical formulations. A pharmaceutically acceptable carrier is preferably one that exhibits no pharmacological action at the dosage of the formulation, is harmless, and does not interfere with the therapeutic effect of the active ingredient. Pharmaceutically acceptable carriers can also be used for purposes such as enhancing the usefulness of the active ingredient and formulation, facilitating formulation, stabilizing quality, or improving usability. Specifically, substances such as those described in "Dictionary of Pharmaceutical Additives," published by Yakuji Nipposha in 2000 (edited by the Japan Pharmaceutical Additives Association) can be appropriately selected depending on the purpose.

[0074] The compounds of the present disclosure are administered to mammals (preferably humans, more preferably human patients) in a pharmaceutically effective amount. The dosage of the compounds of the present disclosure will inevitably vary depending on factors such as age, body weight, symptoms, the desired therapeutic effect, the route of administration, and the duration of treatment. Generally, the compounds are administered orally in a single dose of 0.1 ng to 1000 mg per patient, or parenterally or intravenously in a single dose of 0.01 ng to 100 mg per patient. Of course, as mentioned above, the dosage will vary depending on various conditions, and therefore, a smaller amount than the above may be sufficient, or a larger amount may be required.

[0075] Examples of dosage forms used for administration include oral preparations (e.g., tablets, capsules, granules, powders, oral liquids, syrups, oral jellies, etc.), oral preparations (e.g., oral tablets, oral sprays, oral semisolids, mouthwashes, etc.), injectable preparations (e.g., injectable preparations, etc.), dialysis preparations (e.g., dialysis preparations, etc.), inhalation preparations (e.g., inhalants, etc.), ophthalmic preparations (e.g., eye drops, eye ointments, etc.), otic preparations (e.g., ear drops, etc.), nasal preparations (e.g., nasal drops, etc.), rectal preparations (e.g., suppositories, rectal semisolids, enteral injections, etc.), vaginal preparations (e.g., vaginal tablets, vaginal suppositories, etc.), and dermatological preparations (e.g., solid preparations for topical application, liquid preparations for topical application, sprays, ointments, creams, gels, patches, etc.).

[0076] [Oral Formulations] Oral formulations include, for example, tablets, capsules, granules, powders, oral liquids, syrups, and oral jellies. Oral formulations include rapidly disintegrating formulations in which the release of the active ingredient from the formulation is not specifically controlled, and modified-release formulations, such as enteric-coated formulations and sustained-release formulations, in which the release is controlled according to the purpose through a specific formulation design and manufacturing method. Enteric-coated formulations are designed to release the active ingredient primarily in the small intestine rather than in the stomach, for purposes such as preventing the active ingredient from being decomposed in the stomach or reducing the irritating effect of the active ingredient on the stomach. They are typically prepared by coating with an acid-insoluble enteric base. Sustained-release formulations are formulations in which the release rate, release time, and release site of the active ingredient from the formulation are controlled for purposes such as reducing the frequency of administration or reducing side effects. They are typically prepared by using an appropriate sustained-release agent. Among preparations for oral administration, capsules, granules, tablets, etc. may be coated with an appropriate coating agent such as a sugar, sugar alcohol, or polymer compound for the purpose of facilitating administration or preventing decomposition of the active ingredient.

[0077] (1) Tablets Tablets are solid preparations having a certain shape that are administered orally, and include those generally called tablets, such as plain tablets, film-coated tablets, sugar-coated tablets, multi-layer tablets, and dry-coated tablets, as well as orally rapidly disintegrating tablets, chewable tablets, effervescent tablets, dispersible tablets, and dissolving tablets. When manufacturing plain tablets, the following methods (a), (b), or (c) are usually used: (a) Additives such as excipients, binders, and disintegrants to the active ingredient and mix to form a homogeneous mixture, then granulate using a suitable method using water or a solution containing a binder, then add lubricants and mix, and then compress; (b) Additives such as excipients, binders, and disintegrants to the active ingredient and mix to form a homogeneous mixture, and then directly compress; or Additives such as excipients and binders to granules prepared in advance with additives, then mix to form a homogeneous mixture, and then compress; (c) Additives such as excipients and binders to the active ingredient and mix to form a homogeneous mixture, then wet the mixture with a solvent and pour it into a mold, then mold, and then dry it using a suitable method. Film-coated tablets can usually be produced by coating plain tablets with a thin coating of an appropriate coating agent such as a polymer compound. Sugar-coated tablets can usually be produced by coating plain tablets with a coating agent containing sugars or sugar alcohols. Multilayer tablets can be produced by stacking powders of different compositions in layers and compressing them using an appropriate method. Dry-coated tablets can be produced by coating an inner core tablet with an outer layer of different composition. Tablets can also be made into enteric-coated or sustained-release tablets using appropriate known methods. Orally rapidly disintegrating tablets, chewable tablets, effervescent tablets, dispersible tablets, and dissolving tablets are tablets that have unique functions imparted to them by appropriate selection of additives, and can be produced in accordance with the manufacturing methods for the aforementioned tablets. Orally rapidly disintegrating tablets are tablets that can be taken by quickly dissolving or disintegrating in the oral cavity; chewable tablets are tablets that are taken by chewing; effervescent tablets are tablets that dissolve or disperse in water while rapidly effervescent; dispersible tablets are tablets that are taken by dispersing in water; and dissolving tablets are tablets that are taken by dissolving in water. Effervescent tablets can be produced by using appropriate acidic substances, carbonates, bicarbonates, etc. as additives.

[0078] (2) Capsules Capsules are preparations filled into capsules or encapsulated with a capsule base, and include hard capsules, soft capsules, etc. Hard capsules can be produced by mixing the active ingredient with additives such as excipients to form a homogeneous mixture, or by forming a granular or shaped product using an appropriate method, and then filling the mixture directly into a capsule or by lightly shaping it. Soft capsules can be produced by encapsulating the active ingredient with additives and encapsulating it into a specific shape using an appropriate capsule base such as gelatin whose plasticity has been increased by adding glycerin, D-sorbitol, etc. Capsules can also be made into enteric capsules or sustained-release capsules using appropriate known methods, and coloring agents, preservatives, etc. can also be added to the capsule base.

[0079] (3) Granules Granules are formulations granulated into a granular form, and include not only those commonly referred to as granules but also effervescent granules. Granules are typically produced using one of the following methods (a), (b), or (c): (a) adding excipients, binders, disintegrants, or other additives to a powdered active ingredient, blending them to homogenize, and then granulating them by an appropriate method; (b) adding excipients or other additives to a pre-granulated active ingredient, blending them to homogenize; (c) adding excipients or other additives to a pre-granulated active ingredient, blending them, and then granulating them by an appropriate method. Granules can be coated as needed, and can also be made into enteric-coated or sustained-release granules using known appropriate methods. Effervescent granules can be produced by using appropriate acidic substances, carbonates, bicarbonates, etc. as additives. Effervescent granules refer to granules that rapidly effervescently dissolve or disperse in water. Granules can also be made into fine granules by adjusting the particle size.

[0080] (4) Powders Powders are powdered preparations, and can usually be produced by adding excipients or other additives to the active ingredient, mixing them together, and making them homogeneous.

[0081] (5) Oral Liquids Oral liquids are liquid or fluid, viscous gel-like preparations, and include those commonly referred to as oral liquids, as well as elixirs, suspensions, emulsions, and lemonades. Oral liquids are typically prepared by adding additives and purified water to the active ingredient, mixing to form a homogeneous solution, or emulsifying or suspending the mixture, and filtering as needed. Elixirs are clear, liquid oral liquids containing sweet and aromatic ethanol. They are typically prepared by dissolving a solid active ingredient or its extract in ethanol, purified water, flavoring agents, and sucrose, other sugars, or sweeteners, and then filtering or otherwise preparing a clear liquid. Suspensions are oral liquids in which the active ingredient is finely and homogeneously suspended. They are typically prepared by adding a suspending agent or other additives and purified water or oil to the solid active ingredient, suspending the mixture in an appropriate manner, and homogenizing the entire mixture. An emulsion is an oral liquid preparation in which the active ingredient is finely and homogeneously emulsified, and can usually be produced by adding an emulsifier and purified water to the liquid active ingredient, emulsifying it in an appropriate manner, and making the whole homogeneous. Meanwhile, a lemonade is a clear, liquid oral preparation with a sweet and sour taste.

[0082] (6) Syrups Syrups are viscous liquid or solid preparations containing sugars or sweeteners, including syrup preparations. Syrups can typically be prepared by adding an active ingredient to a solution of sucrose, other sugars, or sweeteners, or to a simple syrup, dissolving, mixing, suspending, or emulsifying the mixture, boiling the mixture as needed, and then filtering it while hot. Syrup preparations refer to granular or powder preparations that become syrups upon addition of water, and are sometimes referred to as dry syrups. Syrup preparations can typically be prepared using sugars or sweeteners as additives, following the manufacturing methods for the granules or powders described above.

[0083] (7) Oral Jelly Preparations Oral jellies are formulations in the form of a molded gel with no fluidity, and can usually be produced by adding an additive and a polymer gel base to the active ingredient, mixing them, gelling them using an appropriate method, and molding them into a specific shape.

[0084] [Injectable Preparations] (1) Injectable Preparations Injectable preparations are solutions, suspensions, or emulsions, or solid sterile preparations that are dissolved or suspended immediately before use and are administered subcutaneously, intramuscularly, or directly into body tissues or organs such as blood vessels. In addition to what is generally called an injectable preparation, these include freeze-dried injectable preparations, powder injectable preparations, pre-filled syringes, cartridges, infusion solutions, implantable injectable preparations, and sustained-release injectable preparations. Injectable preparations are usually produced using the following methods (a) or (b): (a) the active ingredient, either as it is or with additives added, is dissolved, suspended, or emulsified in water for injection, other aqueous solvents, or non-aqueous solvents to form a homogeneous mixture, which is then filled into an injectable container, sealed, and sterilized; (b) the active ingredient, either as it is or with additives added, is dissolved, suspended, or emulsified in water for injection, other aqueous solvents, or non-aqueous solvents to form a homogeneous mixture, which is then sterile-filtered, or a homogeneous mixture prepared aseptically is filled into an injectable container, and sealed; Freeze-dried injections can typically be produced by dissolving the active ingredient directly or with additives such as excipients in water for injection, sterile filtering, and filling into an injection container followed by freeze-drying, or by freeze-drying in a dedicated container and then filling directly into a container. Powder injections can typically be produced by processing through sterile filtration, followed by crystallization to obtain a powder, or by adding sterilized additives to the powder, and then filling into an injection container. Pre-filled syringes can typically be produced by filling a syringe with the active ingredient directly, or by preparing a solution, suspension, or emulsion using the active ingredient and additives. Cartridges refer to injections that are used by placing a cartridge filled with a drug solution into a dedicated syringe. Cartridges filled with a drug solution can typically be produced by filling the cartridge with the active ingredient directly, or by preparing a solution, suspension, or emulsion using the active ingredient and additives. Infusion solutions refer to injections that are typically 100 mL or more and are administered intravenously. An implantable injection is a solid or gel-like injection that is administered subcutaneously, intramuscularly, etc. using an implantation device or by surgery, with the aim of releasing the active ingredient over a long period of time.An implantable injection can usually be produced by using a biodegradable polymer compound and forming it into pellets, microspheres, or gels. A sustained-release injection is an injection that is administered intramuscularly or the like for the purpose of releasing the active ingredient over a long period of time, and can usually be produced by dissolving or suspending the active ingredient in vegetable oil or the like, or by forming it into a suspension of microspheres using a biodegradable polymer compound.

[0085] The disclosed compounds may be administered as a combination agent in combination with other drugs to: 1) complement and / or enhance the prophylactic and / or therapeutic effects of the compound; 2) improve the kinetics and absorption of the compound, reduce the dosage, and / or 3) reduce the side effects of the compound.

[0086] A combination of a compound of the present disclosure and another drug may be administered in the form of a combined preparation in which both components are combined in a single preparation, or in the form of separate preparations. Administration in these separate preparations includes simultaneous administration and administration at different times. Furthermore, administration at different times may involve administering the compound of the present disclosure first and the other drug later, or administering the other drug first and the compound of the present disclosure later. The respective administration methods may be the same or different.

[0087] There are no particular limitations on the diseases for which the above-mentioned combination drug can exert a preventive and / or therapeutic effect, as long as the preventive and / or therapeutic effect of the compound of the present disclosure can be complemented and / or enhanced.

[0088] Examples of other drugs that can be used to complement and / or enhance the preventive and / or therapeutic effects on pain of the compounds of the present disclosure include acetaminophen, nonsteroidal anti-inflammatory drugs, opioid drugs, antidepressants, antiepileptic drugs, N-methyl-D-aspartic acid antagonists, muscle relaxants, antiarrhythmic drugs, steroid drugs, and bisphosphonate drugs.

[0089] Examples of nonsteroidal anti-inflammatory drugs include sazapirin, sodium salicylate, aspirin, aspirin preparations such as aspirin-dialuminate combinations, diflunisal, indomethacin, suprofen, ufenamate, dimethylisopropylazulene, bufexamac, felbinac, diclofenac, tolmetin sodium, clinolil, fenbufen, nabumetone, proglumetacin, indomethacin farnesyl, acemetacin, proglumetacin maleate, amfenac sodium, mofezolac, etodolac, ibuprofen, ibuprofen piconol, naproxen, flurbiprofen, flurbiprofen axetil, and ketamine. Examples include toprofen, fenoprofen calcium, tiaprofen, oxaprozin, pranoprofen, loxoprofen sodium, aluminoprofen, zaltoprofen, mefenamic acid, aluminum mefenamate, tolfenamic acid, floctafenine, ketophenylbutazone, oxyphenbutazone, piroxicam, tenoxicam, ampiroxicam, Napageln ointment, epirizole, tiaramide hydrochloride, tinoridine hydrochloride, emorfazone, sulpyrine, pyrazinone-based cold medicines, phenacetin, dimetotiazine mesylate, meloxicam, celecoxib, rofecoxib, valdecoxib, simetride combination drugs, and non-pyrine-based cold medicines.

[0090] Opioid drugs include, for example, codeine, fentanyl, hydromorphone, levorphanol, meperidine, methadone, morphine, oxycodone, oxymorphone, propoxyphene, and tramadol.

[0091] Examples of antidepressants include tricyclic antidepressants (e.g., amitriptyline hydrochloride, imipramine hydrochloride, clomipramine hydrochloride, dosulepin hydrochloride, nortriptyline hydrochloride, lofepramine hydrochloride, trimipramine maleate, amoxapine, etc.), tetracyclic antidepressants (e.g., maprotiline hydrochloride, mianserin hydrochloride, setiptiline maleate, etc.), monoamine oxidase (MAO) inhibitors (safrazine hydrochloride), serotonin and noradrenaline reuptake inhibitors (SNRIs) (e.g., milnacipran hydrochloride, venlafaxine hydrochloride, etc.), selective serotonin reuptake inhibitors (SSRIs) (e.g., fluvoxamine maleate, paroxetine hydrochloride, fluoxetine hydrochloride, citalopram hydrochloride, etc.), and serotonin reuptake inhibitors (e.g., trazodone hydrochloride, etc.).

[0092] Examples of antiepileptic drugs include phenobarbital, primidone, phenytoin, ethosuximide, zonisamide, nitrazepam, clonazepam, carbamazepine, sodium valproate, acetazolamide, and sulthiame. Examples of N-methyl-D-aspartate antagonists include ketamine hydrochloride, amantadine hydrochloride, memantine hydrochloride, dextromethorphan, and methadone.

[0093] Examples of muscle relaxants include succinylcholine, succinylcholine, vecuronium bromide, pancuronium bromide, and dantrolene sodium.

[0094] Antiarrhythmic drugs include, for example, procainamide, disopyramide, cibenzoline, pirmenol, lidocaine, mexiletine, aprindine, pilsicainide, flecainide, propafenone, propranolol, atenolol, bisoprolol, amiodarone, sotalol, verapamil, diltiazem, and bepridil.

[0095] Steroid drugs include topical drugs, oral drugs, injection drugs, and inhalation drugs. For example, topical drugs include clobetasol propionate, diflorasone acetate, fluocinonide, mometasone furoate, betamethasone dipropionate, betamethasone butyrate propionate, betamethasone valerate, difluprednate, budesonide, diflucortolone valerate, amcinonide, halcinonide, dexamethasone, dexamethasone propionate, and dexamethasone valerate. These include flumethasone, dexamethasone acetate, hydrocortisone acetate, hydrocortisone butyrate, hydrocortisone butyrate propionate, deprodone propionate, prednisolone valerate acetate, fluocinolone acetonide, beclomethasone propionate, triamcinolone acetonide, flumethasone pivalate, alclometasone propionate, clobetasone butyrate, prednisolone, beclomethasone propionate, and fludroxycortide.

[0096] Oral or injectable medications include cortisone acetate, hydrocortisone, hydrocortisone sodium phosphate, hydrocortisone sodium succinate, fludrocortisone acetate, prednisolone, prednisolone acetate, prednisolone sodium succinate, prednisolone butylacetate, prednisolone sodium phosphate, halopredone acetate, methylprednisolone, methylprednisolone acetate, methylprednisolone sodium succinate, triamcinolone, triamcinolone acetate, triamcinolone acetonide, dexamethasone, dexamethasone acetate, dexamethasone sodium phosphate, dexamethasone palmitate, paramethasone acetate, and betamethasone.

[0097] Inhaled medications include beclomethasone propionate, fluticasone propionate, budesonide, flunisolide, triamcinolone, ST-126P, ciclesonide, dexamethasone paromythionate, mometasone furoate, prasterone sulfonate, deflazacort, methylprednisolone suleptanate, and methylprednisolone sodium succinate.

[0098] Bisphosphonate drugs include, for example, etidronate, pamidronate, alendronate, risedronate, zoledronate, and minodronate.

[0099] Any two or more of the other drugs may be administered in combination.

[0100] In addition, other drugs that complement and / or enhance the preventive and / or therapeutic effects of the compounds disclosed herein include not only those that have been discovered so far but also those that will be discovered in the future, based on the above-mentioned mechanisms. Unless otherwise defined, all technical and scientific terms and abbreviations used herein have the same meaning as commonly understood by those skilled in the art to which the present invention pertains. In addition, the contents of all patent and non-patent literature or references explicitly cited in this specification are hereby incorporated by reference as part of this specification.

[0101] In one aspect, the present disclosure provides the following embodiment: [1] General formula (I): (In the formula, R 1 represents a halogen atom; 2 represents (1) a halogen atom, (2) a C1-6 alkyl group, (3) a C2-6 alkenyl group, (4) a C2-6 alkynyl group, (5) a C1-6 alkoxy group, (6) a C1-6 haloalkyl group, (7) a C2-6 haloalkenyl group, (8) a C2-6 haloalkynyl group, or (9) a C1-6 haloalkoxy group, wherein 1 to 2 carbon atoms in the C1-6 alkyl group, C2-6 alkenyl group, C2-6 alkynyl group, C1-6 alkoxy group, C1-6 haloalkyl group, C2-6 haloalkenyl group, C2-6 haloalkynyl group, or C1-6 haloalkoxy group are optionally replaced by nitrogen atoms or optionally oxidized sulfur atoms, and when m represents 2, multiple R 2 may be the same or different, and two R 2represents a C alkyl group, a C alkenyl group, a C alkynyl group, a C alkoxy group, a C haloalkyl group, a C haloalkenyl group, a C haloalkynyl group, or a C haloalkoxy group, it may form a 5- or 6-membered cyclic group together with the carbon atom to which it is attached, 3 represents (1) a halogen atom, (2) a C alkyl group, (3) a C alkenyl group, (4) a C alkynyl group, (5) a C alkoxy group, (6) a C haloalkyl group, (7) a C haloalkenyl group, (8) a C haloalkynyl group, (9) a C haloalkoxy group, or (10) a hydroxyl group; when n is 2 or more, a plurality of R 3 may be the same or different, and two R 3 represents a C1-6 alkyl group, it may be taken together with the carbon atom to which it is attached to form a C3-6 cycloalkyl group, ring1 represents a 3- to 15-membered cyclic group, R 4 is (1) a halogen atom, (2) a C1-6 alkyl group, (3) a C2-6 alkenyl group, (4) a C2-6 alkynyl group, (5) a C1-6 alkoxy group, (6) a C1-6 haloalkyl group, (7) a C2-6 haloalkenyl group, (8) a C2-6 haloalkynyl group, (9) a C1-6 haloalkoxy group, (10) a C1-6 alkylthio group, (11) a C1-6 alkylsulfinyl group, (12) a C1-6 alkylsulfonyl group, (13) a C2-6 acyl group, (14) a 3- to 6-membered cyclic group, (15) -L R4 -(3- to 6-membered cyclic group), (16) hydroxyl group, (17) nitro group, (18) cyano group, (19) oxo group, (20) -NR 401 R 402 , (21)-COOR 403 , (22)-CONR 404 R 405 , or (23)-SO 2 NR 406 R 407wherein 1 to 2 carbon atoms in the C1-6 alkyl group, C2-6 alkenyl group, C2-6 alkynyl group, C1-6 alkoxy group, C1-6 haloalkyl group, C2-6 haloalkenyl group, C2-6 haloalkynyl group, C1-6 haloalkoxy group, C1-6 alkylthio group, C1-6 alkylsulfinyl group, C1-6 alkylsulfonyl group, or C2-6 acyl group may be replaced by an oxygen atom or an optionally oxidized sulfur atom, and when p is 2 or more, a plurality of R 4 may be the same or different, R 4 Among these, groups (2) to (15) are each a group having 1 to 9 R 408 and R 408 is (1) a halogen atom, (2) a C1-4 alkyl group, (3) a C1-4 alkoxy group, (4) a C2-6 acyl group, (5) a C3-6 cycloalkyl group, (6) a hydroxyl group, or (7) -NR 409 R 410 represents R 408 When two or more R are substituted, 408 may be the same or different, and L R4 (1) -O-, (2) -(C1-4 alkylene)-, (3) -O-(C1-4 alkylene)-, (4) -(C1-4 alkylene)-O-, (5) -NR 411 -, (6) -S-, (7) -SO-, or (8) -SO 2 represents -, R 401 , R 402 , R 403 , R 404 , R 405 , R 406 , R 407 , R 409 , R 410 , or R 411 each independently represent (1) a hydrogen atom, (2) a C1-6 alkyl group, (3) a C2-6 acyl group, or (4) a C1-6 alkylsulfonyl group, m represents an integer of 0 to 2, n represents an integer of 0 to 5, and p represents an integer of 0 to 5.), or a pharmaceutically acceptable salt thereof, [2] the compound according to the above [1], wherein ring 1 is a 3- to 10-membered cyclic group, or a pharmaceutically acceptable salt thereof, [3] ring 1 is a ring structure shown below; (In the formula, * indicates the bonding position with the carbonyl group, and the hydrogen atom represented by NH is R 4 [4] The compound according to [1] or [2] above, or a pharmaceutically acceptable salt thereof, wherein R is a ring structure selected from the group consisting of 4 is (1) a halogen atom, (2) a C1-6 alkyl group, (3) a C1-6 alkoxy group, (4) a C1-6 haloalkyl group, (5) a C1-6 haloalkoxy group, (6) a cyclopropyl group, (7) a benzene ring, (8) a pyridine ring, or (9) -COOCH 3 , (10) -COOtBu, or (11) a cyano group, or a pharmaceutically acceptable salt thereof; [5] R 2 is (1) a C1-6 alkyl group, (2) a C1-6 alkoxy group, (3) a C1-6 haloalkyl group, or (4) a C1-6 haloalkoxy group, or a pharmaceutically acceptable salt thereof; [6] The compound represented by general formula (I) is a compound represented by general formula (I-1): (In the formula, R 2-1 represents (1) a C1-6 alkyl group, (2) a C1-6 alkoxy group, (3) a C1-6 haloalkyl group, or (4) a C1-6 haloalkoxy group; R 4-1 is (1) a halogen atom, (2) a C1-6 alkyl group, (3) a C1-6 alkoxy group, (4) a C1-6 haloalkyl group, (5) a C1-6 haloalkoxy group, (6) a cyclopropyl group, (7) a benzene ring, (8) a pyridine ring, or (9) -COOCH 3 , (10) -COOtBu, or (11) a cyano group, and ring1-1 represents the following ring structure: (In the formula, * indicates the bonding position with the carbonyl group, and the hydrogen atom represented by NH is R 4-1(3aS,4R,6aR)-4-[(6-bromo-3-pyridazinyl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl](6,7-dihydro-4H-thieno[3,2-c]pyran-2-yl)methanone, (4) [(3aS,4R,6aR)-4-[(6-bromo-3-pyridazinyl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl](5-methyl-2-thienyl)methanone, (5) [(3aS,4R,6aR)-4-[(6-bromo-3-pyridazinyl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl](5-methyl-2-thienyl)methanone, (6) [(3aS,4R,6aR)-4-[(6-bromo-3-pyridazinyl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl](5-methyl-2-thienyl)methanone, (7) (3) [(3aS,4R,6aR)-4-[(6-bromo-3-pyridazinyl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl](2-methyl-2H-thieno[3,2-c]pyrazol-5-yl)methanone, (4) [(3aS,4R,6aR)-4-[(6-bromo-3-pyridazinyl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl](6-methylpyrazolo[5,1-b][1,3]thiazol-2-yl)methanone, (5) [(3aS,4R,6aR)-4-[(6-bromo-3-pyridazinyl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl](2-cyclopropyl-2H-thieno[3,2-c]pyrazol-5-yl)methanone (6) [(3aS,4R,6aR)-4-[(6-bromo-3-pyridazinyl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl][2-(difluoromethyl)-2H-thieno[3,2-c]pyrazol-5-yl]methanone, (7) [(3aS,4R,6aR)-4-[(6-bromo-3-pyridazinyl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl](6-fluoro-1,3-benzothiazol-2-yl)methanone, (8) [(3aS,4R,6aR)-4-[(6-bromo-3-pyridazinyl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl][5-(difluoromethyl)-2-thienyl]methanone,(9) [(3aS,4R,6aR)-4-[(6-bromo-3-pyridazinyl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl](thieno[3,2-c]pyridin-2-yl)methanone, (10) [(3aS,4R,6aR)-4-[(6-bromo-3-pyridazinyl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl](thieno[3,2-b]furan-5-yl)methanone, (11) [(3aS,4R,6aR)-4-[(6-bromo-3-pyridazinyl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl](1-methyl-1H-thieno[2,3-c]pyrazol-5-yl)methanone, (12) 5-{[(3aS,4R,6aR)-4-[(6-bromo-3-pyridazinyl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl]carbonyl}-2-methyl-3-thiophenecarbonitrile, (13) 2-methyl-2-propanyl 2-[(3aS,4R,6aR)-4-[(6-bromo-3-pyridazinyl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl]carbonyl}-6,7-dihydro[1,3]thiazolo[4,5-c]pyridine-5(4H)-carboxylate, (14) methyl 2-[(3aS,4R,6aR)-4-[(6-bromo-3-pyridazinyl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl]carbonyl}-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-carboxylate, (15) [(3aS,4R,6aR)-4-[(6-bromo-3-pyridazinyl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl](2-phenyl-2H-thieno[3,2-c]pyrazol-5-yl)methanone, (16) [(3aS,4R,6aR)-4-[(6-bromo-3-pyridazinyl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl][2-(3-pyridinyl)-2H-thieno[3,2-c]pyrazol-5-yl]methanone, (17) [(3aS,4R,6aR)-4-[(6-bromo-3-pyridazinyl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl](4,5-dimethyl-1,3-thiazol-2-yl)methanone,(18) methyl 2-[(3aS,4R,6aR)-4-[(6-bromo-3-pyridazinyl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl]carbonyl}-4,7-dihydrothieno[2,3-c]pyridine-6(5H)-carboxylate, (19) [(3aS,4R,6aR)-4-[(6-bromo-3-pyridazinyl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl](4,5,7,8-tetrahydrothieno[2,3-d]oxepin-2-yl)methanone, (20) [(3aS,4R,6aR)-4-[(6-bromo-3-pyridazinyl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl][5-(2-fluoroethoxy)-2-thienyl]methanone, (21) [(3aS,4R,6aR)-4-[(6-bromo-3-pyridazinyl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl](4-fluoro-5-methyl-2-thienyl)methanone, (22) [(3aS,4R,6aR)-4-[(6-chloro-3-pyridazinyl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl](6,7-dihydro-4H-thieno[3,2-c]pyran-2-yl)methanone, (23) [(3aS,4R,6aR)-4-{[6-chloro-4-(trifluoromethyl)-3-pyridazinyl]oxy}hexahydrocyclopenta[c]pyrrol-2(1H)-yl](6,7-dihydro-4H-thieno[3,2-c]pyran-2-yl)methanone, (24) {4-[(5-chloropyrido[2,3-d]pyridazin-8-yl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl}(6,7-dihydro-4H-thieno[3,2-c]pyran-2-yl)methanone, (25) {4-[(4-chlorothieno[2,3-d]pyridazin-7-yl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl}(6,7-dihydro-4H-thieno[3,2-c]pyran-2-yl)methanone, (26) [(3aS,4R,6aR)-4-[(6-chloro-5-methoxy-3-pyridazinyl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl](6,7-dihydro-4H-thieno[3,2-c]pyran-2-yl)methanone,(27) [(3aS,4R,6aR)-4-[(6-chloro-4-methoxy-3-pyridazinyl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl](6,7-dihydro-4H-thieno[3,2-c]pyran-2-yl)methanone, (28) [(3aS,4R,6aR)-4-[(6-chloro-3-pyridazinyl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl](2-methyl-2H-thieno[3,2-c]pyrazol-5-yl)methanone, (29) [(3aS,4S,6aR)-4-[(6-bromo-3-pyridazinyl)oxy]tetrahydro-1H-spiro[cyclopenta[c]pyrrole-5,1′-cyclopropane]-2(3H)-yl](6,7-dihydro-4H-thieno[3,2-c]pyran-2-yl)methanone, (30) [(3aS,4R,6aR)-4-[(6-bromo-3-pyridazinyl)oxy]-3a-methylhexahydrocyclopenta[c]pyrrol-2(1H)-yl](6,7-dihydro-4H-thieno[3,2-c]pyran-2-yl)methanone, (31) [(3aS,4S,6aR)-4-[(6-bromo-3-pyridazinyl)oxy]-5,5-dimethylhexahydrocyclopenta[c]pyrrol-2(1H)-yl](6,7-dihydro-4H-thieno[3,2-c]pyran-2-yl)methanone, (32) [(3aR,4R,6aS)-4-[(6-bromo-3-pyridazinyl)oxy]-3a-hydroxyhexahydrocyclopenta[c]pyrrol-2(1H)-yl](6,7-dihydro-4H-thieno[3,2-c]pyran-2-yl)methanone, (33) [(3aR,4R,6aS)-4-[(6-bromo-3-pyridazinyl)oxy]-3a-methoxyhexahydrocyclopenta[c]pyrrol-2(1H)-yl](6,7-dihydro-4H-thieno[3,2-c]pyran-2-yl)methanone, and (34) [(3aS,4S,5S,6aR)-4-[(6-bromo-3-pyridazinyl)oxy]-5-fluorohexahydrocyclopenta[c]pyrrol-2(1H)-yl](6,7-dihydro-4H-thieno[3,2-c]pyran-2-yl)methanone, or a pharmaceutically acceptable salt thereof.[8] A pharmaceutical composition comprising the compound according to any one of [1] to [7] above, or a pharmaceutically acceptable salt thereof, as an active ingredient, and further comprising a pharmaceutically acceptable carrier; [9] The pharmaceutical composition according to [8] above, which is an ABHD6 inhibitor;

[10] The pharmaceutical composition according to [8] or [9] above, which is an agent for treating and / or preventing a disease associated with ABHD6;

[11] The pharmaceutical composition according to

[10] above, wherein the disease associated with ABHD6 is pain, a neurological disease, an inflammatory disease, an autoimmune disease, a metabolic disease, or a malignant tumor;

[12] The pharmaceutical composition according to

[10] or

[11] , wherein the disease associated with ABHD6 is pain, and the pain is pain associated with osteoarthritis, cancer pain, pain associated with chemotherapy, chronic lower back pain, lower back pain associated with osteoporosis, bone fracture pain, pain associated with rheumatoid arthritis, neuropathic pain, post-herpetic pain, pain associated with diabetic neuropathy, fibromyalgia, pain associated with pancreatitis, pain associated with interstitial cystitis / bladder pain syndrome, pain associated with endometriosis, pain associated with irritable bowel syndrome, migraine, or pain associated with dental pulpitis.

[13] The pharmaceutical composition according to

[10] or

[11] , wherein the ABHD6-related disease is a neurological disease, and the neurological disease is tremor, dyskinesia, dystonia, spasticity, compulsive and obsessive-compulsive behavior, depression, anxiety disorder, panic disorder, acute stress reaction, post-traumatic stress disorder, obsessive-compulsive disorder, agoraphobia, social phobia, mood disorder, epilepsy, traumatic brain injury, spinal cord injury, multiple sclerosis, encephalomyelitis, Parkinson's disease, Huntington's chorea, Alzheimer's disease, or sleep disorder.

[14] The pharmaceutical composition according to any one of [8] to

[13] , wherein the pharmaceutical composition is administered in combination with at least one or more selected from the group consisting of acetaminophen, nonsteroidal anti-inflammatory drugs, opioid drugs, antidepressants, antiepileptic drugs, N-methyl-D-aspartate antagonists, muscle relaxants, antiarrhythmic drugs, steroid drugs, and bisphosphonate drugs.

[15] A therapeutic and / or preventive agent for a disease associated with ABHD6, comprising the compound according to any one of [1] to [7] above or a pharmaceutically acceptable salt thereof.

[16] A method for preventing and / or treating an ABHD6-associated disease, comprising administering to a patient in need thereof a compound according to any one of [1] to [7] above, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to [8] or [9] above;

[17] A compound according to any one of [1] to [7] above, or a pharmaceutically acceptable salt thereof, for use in the prevention and / or treatment of an ABHD6-associated disease;

[18] Use of a compound according to any one of [1] to [7] above, or a pharmaceutically acceptable salt thereof, for the manufacture of an agent for the prevention and / or treatment of an ABHD6-associated disease.

[0102] [Synthesis Examples] The solvents in parentheses shown in the chromatographic separation and TLC sections indicate the elution or development solvents used, and the ratios are by volume. The solvents in parentheses shown in the NMR sections indicate the solvents used in the measurements. The compound names used herein were determined using ACD / Name (registered trademark), a computer program that generally performs naming in accordance with IUPAC rules, or Chemdraw Ultra (version 12.0, Cambridge Soft), or were named in accordance with IUPAC nomenclature. LC-MS / ELSD was performed under the following trifluoroacetic acid (hereinafter referred to as TFA) conditions or formic acid conditions. TFA conditions: Column: YMC Triart C 18 (particle size: 1.9 x 10 -6 m; column length: 30 x 2.0 mm I.D.); flow rate: 1.0 mL / min; column temperature: 30°C; mobile phase (A): 0.1% trifluoroacetic acid aqueous solution; mobile phase (B): 0.1% trifluoroacetic acid-acetonitrile solution; gradient (ratio of mobile phase (A): mobile phase (B) is described): [0 min] 95:5; [0.1 min] 95:5; [1.2 min] 5:95; [1.6 min] 5:95; detector: UV (PDA), ELSD, MS. Formic acid conditions; column: YMC Triart C 18 (particle size: 1.9 x 10 -6m; column length: 30 x 2.0 mm I.D.); flow rate: 1.0 mL / min; column temperature: 30 ° C; mobile phase (A): 0.1% formic acid aqueous solution; mobile phase (B): 0.1% formic acid-acetonitrile solution; gradient (ratio of mobile phase (A): mobile phase (B) is described): [0 min] 95:5; [0.1 min] 95:5; [1.2 min] 5:95; [1.6 min] 5:95; detector: UV (PDA), ELSD, MS. Unless otherwise specified, HPLC retention time indicates the retention time under the conditions described in the LC-MS / ELSD. The description in parentheses next to the HPLC retention time indicates the measurement conditions.

[0103] Reference Example 1: 2-benzylhexahydrocyclopenta[c]pyrrol-4(1H)-one 2-Cyclopentenone (CAS No.: 930-30-3, 17 g) and trifluoroacetic acid (CAS No.: 76-05-1, 240 mg) were added to a dichloromethane solution (600 mL) of N-benzyl-N-(methoxymethyl)-N-trimethylsilylmethylamine (CAS No.: 93102-05-7, 50 g), and the mixture was stirred at room temperature for 16 hours. Triethylamine (430 mg) was added to the reaction mixture, and the mixture was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography to give the title compound (30 g). HPLC retention time (min): 0.65 (TFA); MS (ESI, Pos.): 226 (M+H). + .

[0104] Reference Example 2: (R)—N-((3aS,6aR,E)-2-benzylhexahydrocyclopenta[c]pyrrole-4(1H)-ylidene)-2-methylpropane-2-sulfinamide Titanium(IV) ethoxide (CAS number: 3037-36-3, 46.6 g) and (R)-(+)-2-methyl-2-propanesulfinamide (CAS number: 196929-78-9, 11.8 g) were added to a solution of the compound (20 g) produced in Reference Example 1 in THF (300 mL), and the mixture was stirred at 60° C. for 15 hours. The reaction solution was slowly poured into a saturated aqueous solution of sodium hydrogen carbonate and dichloromethane, and the mixture was filtered. The filtrate was washed with saturated brine, dried over anhydrous sodium sulfate, and then concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography to give the title compound (12.4 g). HPLC retention time (min): 0.80 (TFA); MS (ESI, Pos.): 319 (M+H) + .

[0105] Reference Example 3: (3aS,6aR)-2-benzylhexahydrocyclopenta[c]pyrrol-4(1H)-one To a solution of the compound (20 g) produced in Reference Example 2 in THF (60 mL) was added 2N hydrochloric acid (60 mL) and the mixture was stirred at room temperature for 1 hour. The reaction solution was neutralized with 2N sodium hydroxide and extracted with dichloromethane. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and then concentrated under reduced pressure. The resulting title compound was used in the next reaction without purification.

[0106] Reference Example 4: 2-Methyl-2-propanyl (3aS,6aR)-4-oxohexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate Di-tert-butyl dicarbonate (CAS number: 24424-99-5, 9.4 g) and 20% palladium hydroxide (CAS number: 12135-22-7, 700 mg) were added to a solution of the compound prepared in Reference Example 3 in THF (60 mL), and the mixture was stirred at room temperature under a hydrogen atmosphere for 15 hours. The reaction solution was filtered and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography to give the title compound (7.0 g). 1 H-NMR (CD 3OD): δ3.66-3.53, 3.14, 3.06-2.98, 2.76-2.71, 2.39-2.35, 2.21-2.12, 1.87 1.45.

[0107] Reference Example 5: 2-methyl-2-propanyl (3aS,4S,6aR)-4-hydroxyhexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate. To a solution of the compound prepared in Reference Example 4 (7.3 g) in THF (200 mL) was added 1 M lithium tri-sec-butylborohydride THF solution (CAS number: 38721-52-7, 49 mL) at −78°C, and the mixture was stirred at −78°C for 1 hour. A 35% aqueous hydrogen peroxide solution was slowly added to the reaction solution at 0°C until bubbling ceased, and the mixture was extracted with dichloromethane. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and then concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography to give the title compound (6.5 g). 1 H-NMR (CDCl 3 ): δ4.30-4.25, 3.63-3.50, 3.38-3.30, 3.17-3.15, 2.67, 1.90-1.73, 1.73-1.54, 1.47.

[0108] Reference Example 6: 2-Methyl-2-propanyl (3aS,4R,6aR)-4-(formyloxy)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate Triphenylphosphine (4.50 g) and formic acid (1.29 mL) were added to a solution of the compound (2.6 g) produced in Reference Example 5 in THF (26 mL). After cooling the reaction solution to 0°C, diethyl azodicarboxylate (2.2 M toluene solution, 7.8 mL) was added dropwise, and the mixture was stirred at room temperature for 5 hours. After concentrating the reaction solution, the precipitate was filtered off, and the filtrate was concentrated. The residue was purified by silica gel column chromatography to give the title compound (2.69 g). TLC: Rf = 0.59 (hexane:ethyl acetate = 1:1); 1 H-NMR (CDCl 3 ): δ8.03-8.00, 5.07, 3.65-3.46, 3.29-3.13, 2.82, 2.72-2.63, 2.14-2.00, 1.84-1.73, 1.61, 1.45.

[0109] Reference Example 7: 2-methyl-2-propanyl (3aS,4R,6aR)-4-hydroxyhexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate Potassium carbonate (4.30 g) was added to a solution of the compound produced in Reference Example 6 (2650 mg) in methanol (27 mL), and the mixture was stirred at room temperature for 3 hours. The reaction solution was concentrated, then water was added, and the mixture was extracted with ethyl acetate. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, and then concentrated under reduced pressure. The obtained title compound was used in the next reaction without purification.

[0110] Reference Example 8: 2-Methyl-2-propanyl (3aS,4R,6aR)-4-[(6-bromo-3-pyridazinyl)oxy]hexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate To a solution of the compound produced in Reference Example 7 in N,N-dimethylacetamide (hereinafter, DMA) (25 mL) was added sodium hydride (60% by weight, 955 mg) at 0°C and stirred for 30 minutes. 3,6-Dibromopyridazine (CAS number: 17973-86-3, 4.94 g) was added to the reaction solution and stirred at room temperature for 2 hours. Water was added to the reaction solution, and the mixture was extracted with dichloromethane. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and then concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography to give the title compound (2.8 g). HPLC retention time (min): 1.186 (TFA); MS (ESI, Pos.): 384 (M+H) + .

[0111] Reference Example 9: (3aS,4R,6aR)-4-[(6-bromo-3-pyridazinyl)oxy]octahydrocyclopenta[c]pyrrole. Trifluoroacetic acid (4.1 mL) was added to a dichloromethane (10 mL) solution of the compound prepared in Reference Example 8 (2.56 g), and the mixture was stirred at room temperature for 18 hours. After concentrating the reaction mixture, methanol (30 mL) and AMBERLYST A26 HYDROXIDE FORM (trade name, CAS number: 39339-85-0, 23 g) were added, and the mixture was stirred at room temperature for 15 minutes. After filtering the reaction mixture, the filtrate was concentrated to give the title compound (1.83 g). HPLC retention time (min): 0.718 (TFA); MS (ESI, Pos.): 284 (M+H). + ;1 H-NMR (CDCl 3 ): δ7.46, 6.81, 5.32-5.28, 3.21, 3.08, 2.79-2.65, 2.56, 2.09-1.98, 1.97-1.84, 1.55-1.43.

[0112] Reference Example 10: Methyl 2-methyl-2H-thieno[3,2-c]pyrazole-5-carboxylate Cesium carbonate (7.2 g) and methyl iodide (1.6 g) were added to a solution of methyl 1H-thieno[3,2-c]pyrazole-5-carboxylate (CAS number: 1246552-43-1, 2.0 g) in THF (40 mL), and the mixture was stirred at room temperature for 3 hours. 2N hydrochloric acid was added to the reaction solution, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and then concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography to give the title compound (1.05 g). 1 H-NMR (CDCl 3 ): δ7.70, 7.66, 4.06, 3.93.

[0113] Reference Example 11: 2-methyl-2H-thieno[3,2-c]pyrazole-5-carboxylic acid To a solution of the compound produced in Reference Example 10 (20 mg) in methanol (1 mL) was added 2N aqueous sodium hydroxide solution (0.5 mL) and the mixture was stirred at 60°C for 1 hour. 1N hydrochloric acid was added to the reaction solution, which was then extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and then concentrated under reduced pressure. The resulting residue was used in the next reaction without purification.

[0114] Reference Example 12: Methyl 2-cyclopropyl-2H-thieno[3,2-c]pyrazole-5-carboxylate To a solution of methyl 1H-thieno[3,2-c]pyrazole-5-carboxylate (1.0 g) in dichloroethane (20 mL), cyclopropylboronic acid (CAS number: 873072-42-5, 940 mg), sodium carbonate (CAS number: 497-19-8, 1200 mg), copper(II) acetate (CAS number: 142-71-2, 1.1 g), and 1,10-phenanthroline (CAS number: 66-71-7, 1.1 g) were added and the mixture was stirred at 70°C for 15 hours. 1N hydrochloric acid was added to the reaction solution, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and then concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography to give the title compound (200 mg). HPLC retention time (min): 1.00 (formic acid); MS (ESI, Pos.): 223 (M+H) + .

[0115] Reference Example 13: 2-Cyclopropyl-2H-thieno[3,2-c]pyrazole-5-carboxylic acid To a solution of the compound produced in Reference Example 12 (20 mg) in methanol (1 mL) was added 2N aqueous sodium hydroxide solution (0.5 mL) and the mixture was stirred at 60°C for 1 hour. 1N hydrochloric acid was added to the reaction solution, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and then concentrated under reduced pressure. The resulting residue was used in the next reaction without purification.

[0116] Reference Example 14: Methyl 2-(difluoromethyl)-2H-thieno[3,2-c]pyrazole-5-carboxylate Sodium chlorodifluoroacetate (CAS number: 1895-39-2, 2100 mg) and potassium carbonate (1900 mg) were added to a solution of methyl 1H-thieno[3,2-c]pyrazole-5-carboxylate (500 mg) in DMF (10 mL), and the mixture was stirred at 100°C for 20 hours. Water was added to the reaction solution, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and then concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography to give the title compound (85 mg).

[0117] Reference Example 15: 2-(Difluoromethyl)-2H-thieno[3,2-c]pyrazole-5-carboxylic acid To a solution of the compound produced in Reference Example 14 (20 mg) in methanol (1 mL) was added 2N aqueous sodium hydroxide solution (0.5 mL), and the mixture was stirred at 60°C for 1 hour. 1N hydrochloric acid was added to the reaction solution, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and then concentrated under reduced pressure. The resulting residue was used in the next reaction without purification.

[0118] Reference Example 16: Methyl 4-cyano-5-methyl-2-thiophenecarboxylate Copper cyanide (CAS number: 544-92-3, 304 mg) was added to a solution of methyl 4-bromo-5-methyl-2-thiophenecarboxylate (CAS number: 237385-15-8, 160 mg) in DMF (1 mL), and the mixture was stirred at 140°C for 6 hours. Water was added to the reaction solution, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and then concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography to give the title compound (53 mg). TLC: Rf 0.31 (ethyl acetate:n-hexane=9:1).

[0119] Reference Example 17: 4-cyano-5-methyl-2-thiophenecarboxylic acid To a solution of the compound prepared in Reference Example 16 (20 mg) in methanol (0.4 mL) and THF (0.2 mL) was added 2N aqueous sodium hydroxide solution (0.1 mL) and stirred at room temperature for 2 hours. 2N hydrochloric acid was added to the reaction solution, and the organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and then concentrated under reduced pressure. The obtained title compound was used in the next reaction without purification. HPLC retention time (min): 0.95 (TFA).

[0120] Reference Example 18: Methyl 2-phenyl-2H-thieno[3,2-c]pyrazole-5-carboxylate Phenylboronic acid (CAS number: 98-80-6, 200 mg), copper(II) acetate (110 mg), and pyridine (0.44 mL) were added to a DMF solution (2 mL) of methyl 1H-thieno[3,2-c]pyrazole-5-carboxylate (CAS number: 1246552-43-1), and the mixture was stirred at room temperature for 15 hours. Water was added to the reaction solution, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and then concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography to give the title compound (55 mg). TLC: Rf 0.35 (ethyl acetate:n-hexane=9:1).

[0121] Reference Example 19: 2-Phenyl-2H-thieno[3,2-c]pyrazole-5-carboxylic acid The title compound was obtained by carrying out a reaction similar to that of Reference Example 11 using the compound prepared in Reference Example 18 instead of the compound prepared in Reference Example 10. HPLC retention time (min): 1.00 (TFA); MS (ESI, Pos.): 245 (M+H). + .

[0122] Reference Example 20: Methyl 2-(3-pyridinyl)-2H-thieno[3,2-c]pyrazole-5-carboxylate To a DMF solution (2 mL) of methyl 1H-thieno[3,2-c]pyrazole-5-carboxylate, 3-iodopyridine (CAS number: 1120-90-7, 112 mg), copper(I) iodide (CAS number: 7681-65-4, 20 mg), N,N'-dimethylethylenediamine (CAS number: 110-70-3, 0.02 mL), and cesium carbonate (304 mg) were added and stirred at room temperature for 15 hours. Water was added to the reaction solution, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and then concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography to give the title compound (10 mg). TLC: Rf 0.35 (ethyl acetate:n-hexane=2:3).

[0123] Reference Example 21: 2-(3-pyridinyl)-2H-thieno[3,2-c]pyrazole-5-carboxylic acid The title compound was obtained by carrying out a reaction similar to that in Reference Example 11 using the compound prepared in Reference Example 20 instead of the compound prepared in Reference Example 10. HPLC retention time (min): 0.74 (TFA); MS (ESI, Pos.): 246 (M+H). + .

[0124] Reference Example 22: 4,7-Dihydrothieno[2,3-c]pyridine-2,6(5H)-dicarboxylate dimethyl methyl 4,5,6,7-tetrahydrothieno[2,3-c]pyridine-2-carboxylate hydrochloride (CAS number: 1956377-82-4, 11.5 mg) was added to a dichloromethane solution (0.50 mL) with methyl chloroformate (7.0 μL), triethylamine (7.0 μL), and N,N-dimethylaminopyridine (0.60 mg), and the mixture was stirred at room temperature for 16 hours. 1N hydrochloric acid was added to the reaction solution, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and then concentrated under reduced pressure. The title compound obtained was used in the next reaction without purification. HPLC retention time (min): 1.00 (TFA); MS (ESI, Pos.): 256 (M+H) + .

[0125] Reference Example 23: 6-(Methoxycarbonyl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-2-carboxylic acid To a mixed solution of the compound prepared in Reference Example 22 in THF (0.6 mL) and methanol (0.2 mL), 2N aqueous sodium hydroxide solution (0.2 mL) was added and the mixture was stirred at 60°C for 1 hour. 1N hydrochloric acid was added to the reaction solution, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and then concentrated under reduced pressure. The obtained title compound was used in the next reaction without purification.

[0126] Reference Example 24: 5-(2-Fluoroethoxy)-2-thiophenecarboxylic acid To a solution of 2-fluoroethanol (CAS number: 371-62-0, 1.58 g) in DMA (15 mL) were added sodium hydride (60% by weight, 1.30 g) and 5-fluoro-2-thiophenecarboxylic acid (600 mg) successively at room temperature. The reaction solution was heated to 100°C and stirred for 18 hours. Hydrochloric acid was added to the reaction solution, and the mixture was extracted with an ethyl acetate / hexane solution. The organic phase was washed with water, dried over anhydrous sodium sulfate, and then concentrated under reduced pressure. The title compound obtained was used in the next reaction without purification.

[0127] Example 1: [(3aS,4R,6aR)-4-[(6-bromo-3-pyridazinyl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl](6,7-dihydro-4H-thieno[3,2-c]pyran-2-yl)methanone To a solution of the compound prepared in Reference Example 9 (1100 mg) and 6,7-dihydro-4H-thieno[3,2-c]pyran-2-carboxylic acid (CAS: 933747-41-2, 820 mg) in DMA (17 mL), N,N-diisopropylethylamine (hereinafter referred to as DIPEA) (2.0 mL) and HATU (1500 mg) were added and stirred at room temperature for 3 hours. 2N hydrochloric acid was added to the reaction solution, and the mixture was extracted with dichloromethane. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and then concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography to give the title compound (1350 mg). HPLC retention time (min): 1.06 (TFA); MS (ESI, Pos.): 450 (M+H). + ; 1 H-NMR (CDCl 3 ): δ7.49, 7.15, 6.83, 5.39, 4.71, 4.08, 3.88-4.04, 3.80, 3.64, 2.87-2.97, 2.11-2.33, 1.93-2.04, 1.59-1.69, 1.19-1.32.

[0128] Examples 1-1 to 1-20 The title compounds were obtained by the same procedure as in Example 1, except that corresponding carboxylic acid compounds were used in place of 6,7-dihydro-4H-thieno[3,2-c]pyran-2-carboxylic acid.

[0129] Example 1-1: [(3aS,4R,6aR)-4-[(6-bromo-3-pyridazinyl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl](5-methyl-2-thienyl)methanone HPLC retention time (min): 1.10 (TFA); MS (ESI, Pos.): 408 (M+H) + ; 1 H-NMR (DMSO-d 6 ): δ7.88, 7.41, 7.23, 7.86, 5.32, 4.12-3.47, 2.94-2.80, 2.47, 2.17, 2.04, 1.86, 1.55.

[0130] Example 1-2: [(3aS,4R,6aR)-4-[(6-bromo-3-pyridazinyl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl](2-methyl-2H-thieno[3,2-c]pyrazol-5-yl)methanone HPLC retention time (min): 1.00 (TFA); MS (ESI, Pos.): 448 (M+H) + ; 1 H-NMR (CDCl 3 ): δ7.57, 7.52-7.42, 6.83, 5.41, 4.12, 3.95, 3.83, 3.68, 3.49, 2.95, 2.36-2.27, 2.22-2.12, 2.01-1.93, 1.69-1.59, 1.52-1.38.

[0131] Example 1-3: [(3aS,4R,6aR)-4-[(6-bromo-3-pyridazinyl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl](6-methylpyrazolo[5,1-b][1,3]thiazol-2-yl)methanone HPLC retention time (min): 1.04 (TFA); MS (ESI, Pos.): 448 (M+H) + ; 1 H-NMR (DMSO-d 6): δ8.07, 7.52-7.47, 6.87-6.81, 6.15, 5.40, 4.10, 3.92, 3.83, 3.65, 2.97, 2.43-2.29, 2.27-2.11, 2.08-1.92, 1.64, 1.44.

[0132] Example 1-4: [(3aS,4R,6aR)-4-[(6-bromo-3-pyridazinyl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl](2-cyclopropyl-2H-thieno[3,2-c]pyrazol-5-yl)methanone HPLC retention time (min): 1.07 (TFA); MS (ESI, Pos.): 474 (M+H) + ; 1 H-NMR (CDCl 3 ): δ7.67, 7.49-7.47, 7.40, 6.84-6.81, 5.39, 4.17-4.03, 4.01-3.90, 3.87-3.77, 3.71-3.64, 3.02-2.89, 2.37-2.24, 2.23-2.11, 2.02-1.93, 1.70-1.58, 1.34-1.22, 1.17-1.08.

[0133] Example 1-5: [(3aS,4R,6aR)-4-[(6-bromo-3-pyridazinyl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl][2-(difluoromethyl)-2H-thieno[3,2-c]pyrazol-5-yl]methanone HPLC retention time (min): 1.08 (TFA); MS (ESI, Pos.): 483 (M+H) + ; 1 H-NMR (CDCl 3 ): δ8.01, 7.49, 7.42, 7.34, 6.83, 4.12, 3.68, 2.95, 2.30, 2.17, 2.05, 2.04-1.90, 1.79-1.60, 1.61-1.56, 1.50, 1.37-1.28, 1.34-1.19.

[0134] Example 1-6: [(3aS,4R,6aR)-4-[(6-bromo-3-pyridazinyl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl](6-fluoro-1,3-benzothiazol-2-yl)methanone HPLC retention time (min): 1.25 (TFA); MS (ESI, Pos.): 463 (M+H) + ; 1 H-NMR (DMSO-d 6 ): δ8.25-8.18, 8.12, 7.89, 7.52-7.48, 7.24, 5.37, 4.54-4.30, 4.22-4.10, 4.00-3.82, 3.76-3.49, 3.08-2.80, 2.32-2.25, 2.12-2.04, 1.88, 1.67-1.58.

[0135] Example 1-7: [(3aS,4R,6aR)-4-[(6-bromo-3-pyridazinyl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl][5-(difluoromethyl)-2-thienyl]methanone HPLC retention time (min): 1.12 (TFA); MS (ESI, Pos.): 444 (M+H) + ; 1 H-NMR (DMSO-d 6 ): δ7.88, 7.61, 7.50, 7.34, 7.23, 5.33, 4.22-3.42, 3.06-2.75, 2.27, 2.05, 1.86, 1.58.

[0136] Example 1-8: [(3aS,4R,6aR)-4-[(6-bromo-3-pyridazinyl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl](thieno[3,2-c]pyridin-2-yl)methanone HPLC retention time (min): 0.82 (TFA); MS (ESI, Pos.): 445 (M+H) + ; 1 H-NMR (DMSO-d 6): δ9.34-9.27, 8.56, 8.25, 8.17, 7.89, 7.23, 5.37, 4.27-3.66, 3.00, 2.55, 2.30, 2.16-2.03, 1.94-1.82, 1.62.

[0137] Example 1-9: [(3aS,4R,6aR)-4-[(6-bromo-3-pyridazinyl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl](thieno[3,2-b]furan-5-yl)methanone HPLC retention time (min): 1.12 (TFA); MS (ESI, Pos.): 434 (M+H) + ; 1 H-NMR (DMSO-d 6 ): δ8.03, 7.88, 7.82, 7.23, 7.05, 5.35, 4.11-3.57, 3.37-3.34, 2.99-2.79, 2.55-2.52, 2.28, 2.06, 1.90-1.84, 1.59.

[0138] Example 1-10: [(3aS,4R,6aR)-4-[(6-bromo-3-pyridazinyl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl](1-methyl-1H-thieno[2,3-c]pyrazol-5-yl)methanone HPLC retention time (min): 1.02 (TFA); MS (ESI, Pos.): 448 (M+H) + ; 1 H-NMR (DMSO-d 6 ): δ7.90-7.85, 7.62, 7.23, 5.3, 3.95, 3.69-3.47, 3.31-3.28, 2.95, 2.34-2.23, 2.05, 1.91-1.82, 1.63-1.55.

[0139] Example 1-11: 5-{[(3aS,4R,6aR)-4-[(6-bromo-3-pyridazinyl)oxy]hexahydrocyclopenta[c]pyrrole-2(1H)-yl]carbonyl}-2-methyl-3-thiophenecarbonitrile HPLC retention time (min): 1.10 (TFA); MS (ESI, Pos.): 433 (M+H) +; 1 H-NMR (DMSO-d 6 ): δ7.90-7.82, 7.22, 5.41-5.28, 4.12-3.50, 3.01-2.73, 2.64, 2.26, 2.05, 1.85, 1.58.

[0140] Example 1-12: 2-Methyl-2-propanyl 2-[(3aS,4R,6aR)-4-[(6-bromo-3-pyridazinyl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl]carbonyl}-6,7-dihydro[1,3]thiazolo[4,5-c]pyridine-5(4H)-carboxylate HPLC retention time (min): 1.26 (TFA); MS (ESI, Pos.): 550 (M+H) + ; 1 H-NMR (DMSO-d 6 ): δ7.88, 7.23, 5.33, 4.57, 4.36, 4.21-4.15, 4.41-4.14, 4.00, 4.10-3.97, 3.88, 3.79, 3.93-3.75, 3.70-3.66, 3.65-3.43, 3.00, 2.94-2.89, 2.89-2.74, 2.55, 2.24, 2.09-2.01, 1.86, 1.57, 1.44.

[0141] Example 1-13: Methyl 2-[(3aS,4R,6aR)-4-[(6-bromo-3-pyridazinyl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl]carbonyl}-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-carboxylate HPLC retention time (min): 1.079 (TFA); MS (ESI, Pos.): 507 (M+H) + ; 1 H-NMR (CDCl 3 ): δ7.49, 7.19, 6.84, 5.39, 4.55, 4.07, 3.99-3.84, 3.81-3.73, 3.64, 2.98-2.83, 2.34-2.22, 2.21-2.10, 1.97, 1.70-1.62.

[0142] Example 1-14: [(3aS,4R,6aR)-4-[(6-bromo-3-pyridazinyl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl](2-phenyl-2H-thieno[3,2-c]pyrazol-5-yl)methanone HPLC retention time (min): 1.21 (TFA); MS (ESI, Pos.): 510 (M+H) + ; 1 H-NMR (CDCl 3 ): δ8.11, 7.80-7.78, 7.54-7.47, 7.40-7.35, 6.85-6.83, 5.41, 4.25-3.80, 3.77-3.65, 3.03-2.92, 2.40-2.27, 2.23-2.14, 2.05-1.95, 1.73-1.59.

[0143] Example 1-15: [(3aS,4R,6aR)-4-[(6-bromo-3-pyridazinyl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl][2-(3-pyridinyl)-2H-thieno[3,2-c]pyrazol-5-yl]methanone HPLC retention time (min): 0.98 (TFA); MS (ESI, Pos.): 511 (M+H) + ; 1 H-NMR (CDCl 3 ): δ9.10-9.09, 8.63-8.62, 8.17-8.13, 7.53-7.46, 6.85-6.83, 5.41, 4.26-3.79, 3.74-3.64, 3.07-2.91, 2.38-2.27, 2.24-2.13, 2.04-1.97, 1.74-1.62.

[0144] Example 1-16: [(3aS,4R,6aR)-4-[(6-bromo-3-pyridazinyl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl](4,5-dimethyl-1,3-thiazol-2-yl)methanone HPLC retention time (min): 1.16 (TFA); MS (ESI, Pos.): 423 (M+H) + ; 1 H-NMR (DMSO-d 6): δ7.88, 7.23, 5.32, 4.40-4.14, 4.10-3.98, 3.91-3.74, 3.67-3.42, 3.02-2.89, 2.89-2.72, 2.39, 2.34, 2.24, 2.09-2.00, 1.86, 1.63-1.51.

[0145] Example 1-17: Methyl 2-[(3aS,4R,6aR)-4-[(6-bromo-3-pyridazinyl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl]carbonyl}-4,7-dihydrothieno[2,3-c]pyridine-6(5H)-carboxylate HPLC retention time (min): 1.08 (TFA); MS (ESI, Pos.): 507 (M+H) + ; 1 H-NMR (DMSO-d 6 ): δ7.88, 7.64-7.33, 7.22, 5.33, 4.63, 4.12-4.06, 3.79, 3.69-3.61, 3.51-3.46, 3.15-3.04, 3.00, 2.94-2.74, 2.68, 2.55, 2.26, 2.05, 1.87, 1.63-1.52.

[0146] Example 1-18: [(3aS,4R,6aR)-4-[(6-bromo-3-pyridazinyl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl](4,5,7,8-tetrahydrothieno[2,3-d]oxepin-2-yl)methanone HPLC retention time (min): 1.09 (TFA); MS (ESI, Pos.): 464 (M+H) + ; 1 H-NMR (CDCl 3 ): δ7.49, 7.20, 6.84, 5.40, 4.11, 3.93-3.74, 3.64, 3.04-2.85, 2.16, 1.96, 1.69-1.58.

[0147] Example 1-19: [(3aS,4R,6aR)-4-[(6-bromo-3-pyridazinyl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl][5-(2-fluoroethoxy)-2-thienyl]methanone HPLC retention time (min): 1.086 (TFA); MS (ESI, Pos.): 456 (M+H) + ; 1 H-NMR (CDCl 3 ): δ7.49, 7.21, 6.84, 6.26, 5.42-5.37, 4.82-4.79, 4.71-4.67, 4.37-4.34, 4.30-4.27, 4.14-4.04, 3.91, 3.85-3.74, 3.64, 2.93, 2.35-2.25, 2.21-2.11, 2.01-1.93, 1.68-1.57.

[0148] Example 1-20: [(3aS,4R,6aR)-4-[(6-bromo-3-pyridazinyl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl](4-fluoro-5-methyl-2-thienyl)methanone HPLC retention time (min): 1.168 (TFA); MS (ESI, Pos.): 426 (M+H) + ; 1 H-NMR (CD 3 OD): δ7.49, 7.15, 6.84, 5.39, 4.08, 3.91, 3.84-3.72, 3.63, 2.94, 2.37-2.27, 2.22-2.11, 2.07-1.90, 1.72-1.63, 1.61-1.51.

[0149] Example 2: [(3aS,4R,6aR)-4-[(6-chloro-3-pyridazinyl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl](6,7-dihydro-4H-thieno[3,2-c]pyran-2-yl)methanone The title compound was obtained by performing the same procedures as in Reference Example 8, Reference Example 9, and Example 1 using 3,6-dichloropyridazine (CAS number: 141-30-0) instead of 3,6-dibromopyridazine. HPLC retention time (min): 1.04 (TFA); MS (ESI, Pos.): 406 (M+H). + ; 1 H-NMR (CDCl 3): δ7.37, 7.15, 6.93, 5.41, 4.71, 4.08, 4.04-3.88, 3.80, 3.64, 2.97-2.86, 2.34-2.24, 2.23-2.11, 2.01-1.93, 1.68-1.57.

[0150] Examples 2-1 to 2-5: The title compounds were obtained by carrying out the same operations as in Reference Example 8, Reference Example 9, and Example 1 using the corresponding halogen compounds instead of 3,6-dibromopyridazine.

[0151] Example 2-1: [(3aS,4R,6aR)-4-{[6-chloro-4-(trifluoromethyl)-3-pyridazinyl]oxy}hexahydrocyclopenta[c]pyrrol-2(1H)-yl](6,7-dihydro-4H-thieno[3,2-c]pyran-2-yl)methanone HPLC retention time (min): 1.15 (TFA); MS (ESI, Pos.): 496 (M+H) + ; 1 H-NMR (CDCl 3 ): δ7.63, 7.18, 5.57, 4.71, 4.08, 4.04-3.91, 3.85-3.75, 3.69, 3.50, 3.04-2.79, 2.35-2.14, 2.10-1.97, 1.64.

[0152] Example 2-2: {4-[(5-chloropyrido[2,3-d]pyridazin-8-yl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl}(6,7-dihydro-4H-thieno[3,2-c]pyran-2-yl)methanone HPLC retention time (min): 0.99 (TFA); MS (ESI, Pos.): 457 (M+H) + ; 1 H-NMR (DMSO-d 6 ): δ9.34, 8.61, 8.13, 7.35, 5.55, 4.62, 3.89, 3.07-2.91, 2.86-2.80, 2.57-2.52, 2.36, 2.18-1.98, 1.66-1.58.

[0153] Example 2-3: {4-[(4-chlorothieno[2,3-d]pyridazin-7-yl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl}(6,7-dihydro-4H-thieno[3,2-c]pyran-2-yl)methanone HPLC retention time (min): 1.16 (TFA); MS (ESI, Pos.): 462 (M+H) + ; 1 H-NMR (DMSO-d 6 ): δ 8.35, 7.69, 7.35, 5.52, 4.62, 3.89, 2.96, 2.83, 2.31, 2.12, 1.97, 1.60.

[0154] Example 2-4: [(3aS,4R,6aR)-4-[(6-chloro-5-methoxy-3-pyridazinyl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl](6,7-dihydro-4H-thieno[3,2-c]pyran-2-yl)methanone HPLC retention time (min): 1.05 (TFA); MS (ESI, Pos.): 436 (M+H) + ; 1 H-NMR (CDCl 3 ): δ 7.21, 6.35, 5.38, 4.72, 4.17-4.03, 4.01-3.91, 3.84-3.71, 3.66, 3.01-2.84, 2.28, 1.97, 1.64.

[0155] Example 2-5: [(3aS,4R,6aR)-4-[(6-chloro-4-methoxy-3-pyridazinyl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl](6,7-dihydro-4H-thieno[3,2-c]pyran-2-yl)methanone HPLC retention time (min): 1.00 (TFA); MS (ESI, Pos.): 436 (M+H) + ; 1 H-NMR (CDCl 3 ): δ 7.25-7.18, 6.79, 5.39, 4.72, 4.21-4.06, 4.01-3.87, 3.76-3.62, 3.02-2.87, 2.28, 2.01, 1.64.

[0156] Example 3: [(3aS,4R,6aR)-4-[(6-chloro-3-pyridazinyl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl](2-methyl-2H-thieno[3,2-c]pyrazol-5-yl)methanone The title compound was obtained by performing the same procedures as in Reference Example 8, Reference Example 9, and Example 1, using 3,6-dichloropyridazine (CAS number: 141-30-0) instead of 3,6-dibromopyridazine and the compound prepared in Reference Example 11 instead of 6,7-dihydro-4H-thieno[3,2-c]pyran-2-carboxylic acid. HPLC retention time (min): 0.992 (TFA); MS (ESI, Pos.): 404 (M+H). + ; 1 H-NMR (CDCl 3 ): δ7.57, 7.43, 7.37, 6.92, 5.42, 4.12, 3.95, 3.84, 3.68, 3.49, 2.95, 2.37-2.26, 2.22-2.10, 2.02-1.93, 1.71-1.59.

[0157] Reference Example 25: (3aS,6aR)-hexahydrocyclopenta[c]pyrrol-4(1H)-one hydrochloride To a solution of the compound (5.1 g) prepared in Reference Example 4 in methanol (26 mL) was added 4N hydrochloric acid (1,4-dioxane solution, 26 mL), and the mixture was stirred at room temperature for 3 hours and then concentrated under reduced pressure. The resulting residue was azeotroped with toluene to give the title compound (2.8 g).

[0158] Reference Example 26: (3aS,6aR)-2-(6,7-dihydro-4H-thieno[3,2-c]pyran-2-ylcarbonyl)hexahydrocyclopenta[c]pyrrol-4(1H)-one 6,7-Dihydro-4H-thieno[3,2-c]pyran-2-carboxylic acid (4.6 g), DIPEA (13 mL), and HATU (9.5 g) were added to a solution of the compound (2.8 g) produced in Reference Example 25 in DMA (230 mL), and the mixture was stirred at room temperature for 3 hours. Water was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and then concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography to give the title compound (4.1 g).

[0159] Reference Example 27: (3aS,6aR)-2-(6,7-dihydro-4H-thieno[3,2-c]pyran-2-carbonyl)spiro[3,3a,6,6a-tetrahydro-1H-cyclopenta[c]pyrrole-5,1'-cyclopropan]-4-one. 1,8-Diazabicyclo[5.4.0]undec-7-ene (CAS number: 6674-22-2, 0.31 mL) and diphenylvinylsulfonium triflate (CAS number: 247129-88-0, 410 mg) were added to a solution of the compound prepared in Reference Example 26 (300 mg) in dimethyl sulfoxide (7.5 mL), and the mixture was stirred at room temperature for 1 hour. Water and 1N aqueous hydrochloric acid were added to the reaction mixture, which was then extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give the title compound (100 mg). HPLC retention time (min): 0.90 (TFA); MS (ESI, Pos.): 318 (M+H). + .

[0160] Reference Example 28: [(3aS,4S,6aR)-4-hydroxyspiro[1,3,3a,4,6,6a-hexahydrocyclopenta[c]pyrrole-5,1'-cyclopropan]-2-yl]-(6,7-dihydro-4H-thieno[3,2-c]pyran-2-yl)methanone. To a solution of the compound prepared in Reference Example 27 (138 mg) in methanol (2.8 mL) was added sodium borohydride (25 mg) at 0°C, and the mixture was stirred at 0°C for 30 minutes. Water was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and then concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography to give the title compound (15 mg). HPLC retention time (min): 0.847 (TFA); MS (ESI, Pos.): 320 (M+H). + .

[0161] Example 4: [(3aS,4S,6aR)-4-[(6-bromo-3-pyridazinyl)oxy]tetrahydro-1H-spiro[cyclopenta[c]pyrrole-5,1′-cyclopropan]-2(3H)-yl](6,7-dihydro-4H-thieno[3,2-c]pyran-2-yl)methanone The title compound was obtained by carrying out a reaction similar to that in Reference Example 8 using the compound prepared in Reference Example 28 instead of the compound prepared in Reference Example 7. HPLC retention time (min): 1.086 (TFA); MS (ESI, Pos.): 497 (M+H). + ; 1 H-NMR (CDCl 3 ): δ7.48, 7.14, 6.87, 6.87, 5.03-4.78, 4.72, 4.12, 4.03-3.91, 3.79, 3.00, 2.90, 2.50, 2.05, 1.53-1.46, 1.39, 1.33-1.24, 0.91-0.84, 0.81, 0.66, 0.63-0.54.

[0162] Reference Example 29: 6a-Methylhexahydrocyclopenta[c]pyrrole-1,6-dione Potassium carbonate (0.9 g) and methyl iodide (0.27 mL) were added to a solution of hexahydrocyclopenta[c]pyrrole-1,6-dione (CAS number: 1792179-55-8, 300 mg) in acetonitrile (6 mL), and the mixture was stirred at room temperature for 1 hour. The reaction solution was filtered and then concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography to give the title compound (240 mg). 1 H-NMR (Acetonitrile-d 3 ): δ6.23, 3.66-3.47, 3.23-3.03, 2.95-2.69, 2.43-2.14, 1.94-1.68, 1.37-1.10.

[0163] Reference Example 30: 3a-methyloctahydrocyclopenta[c]pyrrol-4-ol Lithium aluminum hydride (131 mg) was added to a solution of the compound prepared in Reference Example 29 (213 mg) in THF (6.4 mL), and the mixture was stirred at 0° C. for 20 minutes. Water, 2N sodium hydroxide, and water were successively added to the reaction mixture, which was then filtered. The filtrate was concentrated under reduced pressure to give the title compound (196 mg). 1 H-NMR (DMSO-d 6 ): δ3.68-3.48, 3.47-3.37, 3.01-2.77, 2.74-2.52, 2.46-2.21, 2.20-2.06, 1.91-1.80, 1.78-1.49, 1.30-1.17, 1.16-0.99, 0.95-0.83.

[0164] Reference Example 31: 6,7-Dihydro-4H-thieno[3,2-c]pyran-2-yl[(3aS,4R,6aR)-4-hydroxy-3a-methylhexahydrocyclopenta[c]pyrrol-2(1H)-yl]methanone The title compound was obtained by carrying out a reaction similar to that in Reference Example 26 using the compound prepared in Reference Example 30 instead of the compound prepared in Reference Example 25. HPLC retention time (min): 0.847 (TFA); MS (ESI, Pos.): 308 (M+H). + .

[0165] Example 5: [(3aS,4R,6aR)-4-[(6-bromo-3-pyridazinyl)oxy]-3a-methylhexahydrocyclopenta[c]pyrrol-2(1H)-yl](6,7-dihydro-4H-thieno[3,2-c]pyran-2-yl)methanone The same reaction as in Reference Example 8 was carried out using the compound prepared in Reference Example 31 instead of the compound prepared in Reference Example 7 to obtain a racemic mixture of the title compounds. The obtained racemic mixture was purified by supercritical fluid chromatography (CHIRALPAK ID, CO 2 The title compound was obtained by optical resolution using a solvent (TFA:ethanol = 55:45). HPLC retention time (min): 1.084 (TFA); MS (ESI, Pos.): 464 (M+H). + ; 1 H-NMR (CDCl 3): δ7.52-7.50, 7.48, 7.31, 7.21, 7.18, 6.87, 6.84, 5.52, 4.71, 3.98, 3.87-3.36, 2.89, 2.67-2.33, 2.22-2.05, 2.00-1.79.

[0166] Reference Example 32: 2-Methyl-2-propanyl (3aS,6aR)-5,5-dimethyl-4-oxohexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate To a solution of the compound produced in Reference Example 4 (5000 mg) in THF (220 mL), potassium tert-butoxide (5230 mg) and methyl iodide (6615 mg) were added at 0°C, and the mixture was stirred at room temperature for 1 hour. A saturated aqueous solution of sodium bicarbonate was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and then concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography to give the title compound (3500 mg).

[0167] Reference Example 33: 2-Methyl-2-propanyl (3aS,4S,6aR)-4-hydroxy-5,5-dimethylhexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate Sodium borohydride (784 mg) was added to a solution of the compound produced in Reference Example 32 (3500 mg) in methanol (70 mL) at 0°C, and the mixture was stirred at room temperature for 1 hour. A saturated aqueous solution of ammonium chloride was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and then concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography to give the title compound (1080 mg).

[0168] Example 6: [(3aS,4S,6aR)-4-[(6-bromo-3-pyridazinyl)oxy]-5,5-dimethylhexahydrocyclopenta[c]pyrrol-2(1H)-yl](6,7-dihydro-4H-thieno[3,2-c]pyran-2-yl)methanone The title compound was obtained by carrying out the same reaction as in Reference Example 8 → Reference Example 9 → Example 1 using the compound prepared in Reference Example 33 instead of the compound prepared in Reference Example 7. HPLC retention time (min): 1.181 (TFA); MS (ESI, Pos.): 477 (M+H).+ ; 1 H-NMR (DMSO-d 6 ) δ 7.88, 7.39, 7.26, 5.08, 4.62, 3.89, 3.72, 3.61, 3.34-3.29, 3.23, 3.00, 2.92-2.74, 2.55, 2.35-2.22, 1.86, 1.46-1.36, 1.09-1.02, 1.06.

[0169] Reference Example 34: 6,7-Dihydro-4H-thieno[3,2-c]pyran-2-yl(3,3a,4,5-tetrahydrocyclopenta[c]pyrrole-2(1H)-yl)methanone The title compound was obtained by a reaction similar to that in Example 1 using 1H,2H,3H,3aH,4H,5H-cyclopenta[c]pyrrole hydrochloride (CAS number: 2361634-32-2) instead of the compound prepared in Reference Example 9. HPLC retention time (min): 1.036 (TFA); MS (ESI, Pos.): 276 (M+H). + .

[0170] Reference Example 35: 6,7-Dihydro-4H-thieno[3,2-c]pyran-2-yl(3a,4-dihydroxyhexahydrocyclopenta[c]pyrrol-2(1H)-yl)methanone To a solution of the compound prepared in Reference Example 34 (365 mg) in THF (3.7 mL) were added 4-methylmorpholine N-oxide 50% aqueous solution (CAS number: 7529-22-8, 0.34 mL) and microencapsulated osmium tetroxide (CAS number: 20816-12-0, 59 mg, 17% content), and the mixture was stirred at room temperature for 10 hours. A saturated aqueous sodium bicarbonate solution was added to the reaction solution, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and then concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography to give the title compound (220 mg). HPLC retention time (min): 0.748 (TFA); MS (ESI, Pos.): 310 (M+H) + .

[0171] Example 7: [(3aR,4R,6aS)-4-[(6-bromo-3-pyridazinyl)oxy]-3a-hydroxyhexahydrocyclopenta[c]pyrrol-2(1H)-yl](6,7-dihydro-4H-thieno[3,2-c]pyran-2-yl)methanone The same reaction as in Reference Example 8 was carried out using the compound prepared in Reference Example 35 instead of the compound prepared in Reference Example 7 to obtain a racemic mixture of the title compounds. The obtained racemic mixture was purified by supercritical fluid chromatography (CHIRALPAK IB, CO 2 The title compound was obtained by optical resolution using a solvent (TFA:methanol=80:20). HPLC retention time (min): 0.921 (TFA); MS (ESI, Pos.): 466 (M+H). + ; 1 H-NMR (CDCl 3 ): δ7.57-7.52, 7.17, 6.96-6.92, 5.49-5.44, 4.71, 4.06-3.88, 3.82, 3.49, 2.90, 2.83, 2.69, 2.45-2.35, 2.27-2.16, 2.09-1.99, 1.43.

[0172] Example 8: [(3aR,4R,6aS)-4-[(6-bromo-3-pyridazinyl)oxy]-3a-methoxyhexahydrocyclopenta[c]pyrrol-2(1H)-yl](6,7-dihydro-4H-thieno[3,2-c]pyran-2-yl)methanone To a solution of the compound prepared in Example 7 (20 mg) in THF (0.3 mL) and DMF (0.03 mL), methyl iodide (0.008 mL) and sodium hydride (60% by weight, 8.6 mg) were added and stirred at room temperature for 3 hours. A saturated aqueous solution of ammonium chloride was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography to give the title compound (19 mg). HPLC retention time (min): 1.00 (TFA); MS (ESI, Pos.): 480 (M+H). + ; 1 H-NMR (CDCl 3): δ7.52, 7.24-7.17, 6.96, 5.75, 4.71, 4.12, 3.99, 3.80, 3.49, 3.28, 2.90, 2.38-2.20, 2.06-1.97, 1.42, 0.82.

[0173] Reference Example 36: (3aS,5S,6aR)-2-(6,7-dihydro-4H-thieno[3,2-c]pyran-2-ylcarbonyl)-5-fluorohexahydrocyclopenta[c]pyrrol-4(1H)-one 2,6-Dimethylpyridine (CAS number: 108-48-5, 1.26 mL) and tert-butyldimethylsilyl trifluoromethanesulfonate (CAS number: 69739-34-0, 2.0 mL) were added to a solution of the compound prepared in Reference Example 26 (792 mg) in dichloromethane (15 mL), and the mixture was stirred at room temperature for 24 hours. A saturated aqueous solution of sodium bicarbonate was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and then concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography. To a solution of the obtained compound in acetonitrile (10 mL) was added 1-chloromethyl-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane bis(tetrafluoroborate) (CAS number: 140681-55-6, 345 mg), and the mixture was stirred at room temperature for 2 hours. A saturated aqueous solution of sodium bicarbonate was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and then concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography to give the title compound (33 mg). HPLC retention time (min): 0.852 (TFA); MS (ESI, Pos.): 310 (M+H) + .

[0174] Example 9: [(3aS,4S,5S,6aR)-4-[(6-bromo-3-pyridazinyl)oxy]-5-fluorohexahydrocyclopenta[c]pyrrol-2(1H)-yl](6,7-dihydro-4H-thieno[3,2-c]pyran-2-yl)methanone The compound prepared in Reference Example 36 was used instead of the compound prepared in Reference Example 4, and the same reactions as in Reference Example 5, Reference Example 6, Reference Example 7, and Reference Example 8 were carried out to obtain the title compound. HPLC retention time (min): 1.00 (TFA); MS (ESI, Pos.): 468 (M+H). + ; 1 H-NMR (CDCl 3 ): δ 7.54, 7.26, 6.89, 5.49, 5.21, 4.72, 4.21, 4.09, 4.00-3.89, 3.78, 3.00-2.88, 2.49-2.32, 2.06-1.92, 1.30-1.28.

[0175] Pharmacological Experimental Example 1: Evaluation of ABHD6 Enzyme Inhibitory Activity

[0049] The substrate, 1-Arachidonoyl Glycerol (Cayman) was prepared in an assay buffer containing 50 mM Tris-HCl (pH 7.4), 100 mM NaCl, and 0.05% BSA to a final concentration of 10 μmol / L, and the compound was added to a final concentration of 0.0003, 0.001, 0.003, 0.01, 0.03, 0.1, 0.3, 1, 3, or 10 μmol / L (DMSO was added to a final concentration of 0.3%). A compound-free group was prepared by adding DMSO to a final concentration of 0.3%. The enzyme reaction was initiated by adding recombinant human ABHD6 (33-337) prepared in the same assay buffer to a final concentration of 300 μg / mL to the mixed solution of the substrate and compound. The recombinant human ABHD6 (33-337) was GST-tagged and was expressed in Escherichia coli, purified with Glutathione-Sepharose 4B resin, and then concentrated. The enzyme reaction was carried out at room temperature using a 384-well polypropylene microplate, and wells to which no enzyme was added were used as the blank group. One hour after the start of the enzyme reaction, arachidonic acid-d was added as an internal standard. 8The enzyme reaction was stopped by adding methanol containing 1% formic acid (Cayman). The top of the enzyme reaction plate was sealed with aluminum foil, and the plate was centrifuged at 560 g for 5 minutes at room temperature. The enzyme reaction product, arachidonic acid, and the internal standard, arachidonic acid-d, were analyzed using a RapidFire (registered trademark)-Mass Spectrometry system. 8 The ratio of each quantitative value was calculated, and the average value of the blank group was set as 100% inhibition, and the average value of the compound-free group was set as 0% inhibition, to calculate the inhibition rate of arachidonic acid production at each compound concentration, and the IC 50 The pharmacological experiments above revealed that the compounds of the present disclosure have potent ABHD6 inhibitory activity. For example, the IC values ​​of some of the compounds of the present disclosure were 50 The values ​​are shown in Table 1 below.

[0176] Pharmacological Experimental Example 2: Measurement of Binding Affinity to Human ABHD6 Using HEK293 cells overexpressing NanoLuc-human ABHD6 fusion protein, a fluorescent probe molecule and a test compound were allowed to competitively interact with each other. The binding affinity of the test compound to human ABHD6 was measured using bioluminescence resonance energy transfer (hereinafter abbreviated as BRET), which is induced by the proximity of the probe molecule and the NanoLuc-human ABHD6 fusion protein, as an indicator. <Compound Treatment> The test compound and the control compound described in Example 2 were dissolved in dimethyl sulfoxide (DMSO) to prepare 10 mmol / L solutions. The prepared 10 mmol / L solutions were thawed prior to use, serially diluted with DMSO, and used in the experiment. <Cell Culture> HEK293 cells expressing NanoLuc-human ABHD6 fusion protein were cultured in 5% CO using inactivated (56°C, 30 minutes) 9.8 vol% non-dialyzed FBS (containing 0.5 vol% geneticin and 1% penicillin-streptomycin). 2 The medium was removed and the cells were cultured at 37°C in the presence of Ca. 2+ and Mg 2+The cells were washed once with phosphate-buffered saline containing no trypsin. An appropriate amount of trypsin-EDTA was added and incubated at room temperature to detach the cells. After that, 10 volumes of medium per trypsin-EDTA (0.05%) was added to stop the enzyme reaction. The cells were collected in a centrifuge tube and centrifuged at 120g for 3 minutes at room temperature, after which the supernatant was removed. The cells were suspended in an appropriate amount of medium and seeded in a culture flask. After preparing HEK293 cells expressing NanoLuc-human ABHD6 fusion protein, 5.0 x 10 cells were cultured in CELLBANKER2. 6 The cells were cryopreserved at 2 × 10 cells / mL / vial and used in the experiment. HBSS(+) containing 20 mmol / L HEPES (pH 7.3) and 0.1% BSA was prepared and used as an assay buffer. The cells were thawed and diluted to 2 × 10 5 The cell suspension (25 μL) was added to a 384-well assay plate to which the test compound had been added beforehand to start the reaction. 2 After standing at 37°C for 30 minutes in the presence of 5% CO, a probe molecule (10 mmol / L in DMSO) having a fluorophore was diluted with the assay buffer to a final concentration of 100 nmol / L, and 15 µL of the diluted probe was added to the assay plate. 2 After incubation at 37°C for 30 minutes in the presence of HCl, Nano-Glo® Vivazine™ substrate (PROMEGA) was diluted with assay buffer according to the method described in the manufacturer's protocol, and 10 μL of this diluted solution was added to the assay plate. After incubation at room temperature for 1 hour, luminescence and fluorescence intensities were measured using the GloMax® Discover system. The ratio of luminescence intensity through a 450 nm band-pass filter to fluorescence intensity through a 600 nm long-pass filter was used as the measured value for each sample. The measured value for the group containing the control substance at a final concentration of 30 μmol / L was defined as 100% inhibition, and the measured value for the group without compound was defined as 0% inhibition. The IC value of the test compound was calculated from the measured values ​​at each test compound concentration. 50 In the above cell evaluation system, the compounds of the present disclosure were found to have strong ABHD6 binding activity. For example, the IC values ​​of some of the compounds of the present disclosure were 50 The values ​​are shown in Table 2 below.

[0177] Pharmacological Experimental Example 3: Evaluation of ABHD6 Selectivity Using rat brain membrane fractions, fluorescent probe molecules and test compounds were reacted with each other. Proteins were separated by electrophoresis, and the binding affinity of the test compounds was measured using the fluorescence intensity of ABHD6, MAGL, and FAAH as indicators. <Compound Treatment> The test compound was dissolved in dimethyl sulfoxide (DMSO) to prepare a 10 mmol / L solution. The prepared 10 mmol / L solution was thawed before use and serially diluted with DMSO to a concentration 50-fold higher than the final concentration. <Rat Brain Membrane Fraction Preparation> After exsanguination under anesthesia, rats were exsanguinated and their brains were removed. 1 mL of ice-cold phosphate buffered saline (PBS, pH 7.5) was added per 200 mg of brain weight, and the mixture was homogenized using a homogenizer. The homogenate solution was centrifuged at 1,000 g for 10 minutes at 4°C, and the supernatant was collected. The resulting supernatant was centrifuged at 100,000 g for 45 minutes at 4°C, and the sediment was resuspended in ice-cold PBS to prepare a membrane fraction. The protein concentration of the prepared brain membrane fraction solution was quantified and stored in a -80°C freezer until use. <ABPP> The brain membrane fraction solution was adjusted to 3 mg / mL with PBS. 1 μL of DMSO or compound solution was added to 50 μL of the 3 mg / mL membrane fraction solution, and the mixture was incubated at 37°C for 30 minutes. Then, 1 μL of a fluorophore-containing probe molecule (ActivX (trade name) TAMRA-FP Serine Hydrolase Probe, final concentration 1 μmol / L, DMSO solution) was added, and the mixture was incubated at room temperature for 30 minutes. The reaction was stopped with 4x sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) loading buffer. After heating the sample at 95°C for 5 minutes, proteins were separated by SDS-PAGE using a 10% acrylamide gel. Fluorescence from the gel after SDS-PAGE was visualized using a Chemiluminescence Imaging System. For each band of ABHD6, MAGL, and FAAH, the fluorescence band intensity of the control group (DMSO-treated group) was defined as 0% inhibition, and the IC of the test compound was calculated from the fluorescence intensity at each test compound concentration. 50As a result, it was found that the compounds of the present disclosure have selective inhibitory activity against ABHD6, MAGL, and FAAH.

[0178] Pharmacological Experimental Example 4: Analgesic Effect on Sodium Monoiodoacetate-Induced Rat Model The analgesic effect of the disclosed compound was evaluated using a rat model induced with sodium monoiodoacetate (hereinafter abbreviated as MIA) (Sigma-Aldrich Japan). (1) Preparation of MIA-Induced Rat Model The rats were anesthetized with isoflurane, and the area around the right hind knee was shaved. 25 μL of 120 mg / mL MIA solution was administered into the right hind joint cavity using a syringe with a 29G needle (BD Lordose, Becton Dickinson Japan). 25 μL of saline was administered to the normal control group. (2) Group Composition and Group Division The group composition was a normal control group, a disease control group, a test substance administration group, and a tramadol or morphine administration group. The right hind paw load weight ratio (measurement method described below) of model rats prepared by the method described above (1) 13 or 14 days after MIA induction was measured for the normal control group. The rats were divided into groups to ensure that the right hind paw load weight ratio was balanced. (3) Administration of Test Substances, Tramadol, or Morphine. The test substance, a compound of the present disclosure, was dissolved in a solubilization medium (Coriphor:PEG = 7:3 solution) to prepare a 0.4 or 8 mg / mL solution. The prepared solution was diluted 4-fold with distilled water to prepare a 0.1 or 2 mg / mL solution (final concentration of solubilization medium: 25%). The positive control drug, tramadol, was dissolved in physiological saline to prepare a 2 mg / mL solution. Alternatively, the positive control drug, morphine, was dissolved in physiological saline to prepare a 0.6 mg / mL solution. The test substance was orally administered at 5 mL / kg 5 hours before the evaluation, and tramadol and morphine were subcutaneously administered at 5 mL / kg 1 hour before the evaluation. (4) Measurement of Right Hind Paw Load Weight Ratio The load weights of the left and right hind paws were measured using a Linton Incapacitance Tester (MJS Technology INC., UK). Specifically, the rat was transferred to a dedicated cage on the Linton Incapacitance Tester and positioned so that the left and right hind paws were placed separately on two pairs of weight measurement sensors. After confirming that the rat's posture was even between the left and right and the front and back, the load weights of the left and right hind paws were measured for 3 seconds. The load weight measurement was repeated three times per rat.To obtain stable measurements, rats were placed in dedicated cages for at least 5 days between the day of MIA induction and 14 days after induction and allowed to acclimate for at least 20 minutes. Furthermore, rats were allowed to acclimate for approximately 10 minutes immediately before measuring the load weight, and then the load weight was measured. 14 days after MIA induction, before grouping, and 14 days after, the left and right hind paw load weights were measured for the normal control group, the disease control group, the test substance administration group (5 hours after administration), the tramadol administration group (1 hour after administration), and the morphine administration group (1 hour after administration). Based on the average left and right hind paw load weights, the right hind paw load weight ratio in both hind paw load weights was calculated using the following formula 1. Based on the right hind paw load weight ratio for each group 14 days after MIA induction, the improvement rate of the right hind paw load weight ratio upon administration of the test substance, a compound of the present disclosure, was calculated using the following formula 2 to evaluate the analgesic effect of the test substance (a compound of the present disclosure). A R A: Load weight of the right hind leg (average value of three measurements of the same animal) L : Load weight of left hind leg (average of three measurements of the same animal) B C B: Mean right hind paw load weight ratio of normal control group N : Mean weight ratio of right hind limb load in the diseased control group B T Average right hind paw load weight ratio in the test substance administration group. As a result, it was found that the analgesic effect of the compound of the present disclosure is equal to or greater than that of tramadol and morphine, which are commonly used as analgesics.

[0179] Pharmacological Experiment Example 5: Antidepressant Effect in Rat Forced Swimming Test The rat forced swimming test can be used to evaluate the antidepressant effect of a compound of the present disclosure. (1) Group Composition and Group Allocation: Groups were divided into a vehicle-administered group, a test substance-administered group, and an imipramine-administered group. Based on body weight on the day of group allocation, subjects were assigned to five groups using stratified randomization. (2) Administration of the Test Substance, Imipramine: The test substance, a compound of the present disclosure, was dissolved in a solubilization medium (Corifor:PEG = 7:3 solution) to prepare a 4 mg / mL solution. The prepared solution was diluted 4-fold with distilled water to prepare a 1 mg / mL solution (final concentration of solubilization medium: 25%). The 1 mg / mL solution was further diluted 10-fold or 100-fold with 25% solubilization medium to prepare a 0.1 mg / mL or 0.01 mg / mL solution. As a positive control, imipramine was dissolved in saline to prepare a 15 mg / mL solution. The test substance was orally administered at 5 mL / kg 5 hours before evaluation, and imipramine was administered intraperitoneally at 2 mL / kg 0.5 hours before evaluation. (3) Measurement of Immobility Time On the day before measurement, rats were placed in a water tank (water depth: 20 cm, water temperature: 24 ± 1°C) and forced to swim for 15 minutes (measurement acclimation). 24 hours later, the rats were placed again in the water tank (water depth: 20 cm, water temperature: 24 ± 1°C) and forced to swim for 5 minutes, and the immobility time during this time was measured as depressive-like behavior. The immobility time was measured using a stopwatch, and the measured value was recorded as an integer rounded to one decimal place.

[0180] Pharmacological Experimental Example 6: Anxiolytic Effect in Rat Social Interaction Test The anxiolytic effect of the disclosed compound can be evaluated using a rat social interaction test. (1) Group Composition and Group Allocation: The group composition is vehicle-administered group, test substance-administered group, and diazepam-administered group. Subjects are randomized into five groups based on their body weight on the day of group allocation using stratified randomization. (2) Administration of Test Substance, Diazepam: The test substance, the disclosed compound, is dissolved in a solubilizing medium (corifol:PEG = 7:3 solution) to prepare a 4 mg / mL solution. The prepared solution is diluted 4-fold with distilled water to prepare a 1 mg / mL solution (final concentration of solubilizing medium: 25%). The 1 mg / mL solution is further diluted 10-fold or 100-fold with 25% solubilizing medium to prepare a 0.1 mg / mL or 0.01 mg / mL solution. As a positive control, diazepam was suspended in 0.5% methylcellulose solution to prepare a 0.6 mg / mL suspension. The test substance was orally administered at 5 mL / kg two hours before evaluation, and diazepam was orally administered at 5 mL / kg one hour before evaluation. (3) Measurement of Social Interaction Time Two hours after administration of the test substance or one hour after administration of the positive control substance, two rats (one pair) with a weight difference of within 20 g were placed in an open field apparatus, and their behavior was videotaped for 10 minutes. From the behavior over the 10 minutes, the time corresponding to the social behavior analysis items listed in Table 3 was measured. If the time for these behaviors is extended, it can be confirmed that the test substance exhibits anxiolytic effects.

[0181] Pharmacological Experiment Example 7: MDR1 Substrate Screening Test Human MDR1-expressing MDCK cells were cultured and an extracellular transport test was performed. Transwell 96-well permeation support (pore size 0.4 μm, surface area 0.143 cm) with a polycarbonate membrane was used. 2Cells were grown in PBS (Life Sciences). Cells were preincubated with Hank's balanced salt solution (HBSS) at 37°C for 10 minutes, after which HBSS containing 1 or 10 μmol / L of test substance was added to the apical compartment (75 μL) or basolateral compartment (250 μL) to initiate extracellular transport. The assay was terminated after 1 hour by separating each assay plate. An aliquot (25 μL) from the opposite compartment was mixed with acetonitrile. After centrifugation, compound concentrations in the supernatant were measured by LC / MS / MS using a UFLC system with a Triple QUAD 5500 column and a Unison UK-C18 HT column (3.0 μm, 2.0 x 20 mm). The apparent permeability (Papp) of the test compound in the receiver wells was measured, and the efflux ratio (ER) for the membrane permeability test was calculated using the following equation 3: Here, Papp, AtoB and Papp, BtoA represent the apparent permeability from the apical membrane to the basolateral membrane and from the basolateral membrane to the apical membrane, respectively. As a result, it was found that the compound of the present disclosure has a low efflux ratio by P-glycoprotein and excellent central transferability.

[0182] [Formulation Example] Formulation Example The following ingredients are mixed by a conventional method and then compressed into tablets to obtain approximately 10,000 tablets, each containing 10 mg of the active ingredient. - [(3aS,4R,6aR)-4-[(6-bromo-3-pyridazinyl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl](6,7-dihydro-4H-thieno[3,2-c]pyran-2-yl)methanone ... 100 g - Carboxymethylcellulose calcium (disintegrant) ... 20 g - Magnesium stearate (lubricant) ... 10 g - Microcrystalline cellulose ... 870 g

[0183] Since the compound of the present disclosure has ABHD6 inhibitory activity, pharmaceuticals containing the compound of the present disclosure as an active ingredient are useful as agents for preventing and / or treating diseases associated with ABHD6.

Claims

1. General formula (I): (In the formula, R 1 represents a halogen atom; 2 represents (1) a halogen atom, (2) a C1-6 alkyl group, (3) a C2-6 alkenyl group, (4) a C2-6 alkynyl group, (5) a C1-6 alkoxy group, (6) a C1-6 haloalkyl group, (7) a C2-6 haloalkenyl group, (8) a C2-6 haloalkynyl group, or (9) a C1-6 haloalkoxy group, wherein 1 to 2 carbon atoms in the C1-6 alkyl group, C2-6 alkenyl group, C2-6 alkynyl group, C1-6 alkoxy group, C1-6 haloalkyl group, C2-6 haloalkenyl group, C2-6 haloalkynyl group, or C1-6 haloalkoxy group are optionally replaced by nitrogen atoms or optionally oxidized sulfur atoms, and when m represents 2, multiple R 2 may be the same or different, and two R 2 represents a C alkyl group, a C alkenyl group, a C alkynyl group, a C alkoxy group, a C haloalkyl group, a C haloalkenyl group, a C haloalkynyl group, or a C haloalkoxy group, it may form a 5- or 6-membered cyclic group together with the carbon atom to which it is attached, 3 represents (1) a halogen atom, (2) a C alkyl group, (3) a C alkenyl group, (4) a C alkynyl group, (5) a C alkoxy group, (6) a C haloalkyl group, (7) a C haloalkenyl group, (8) a C haloalkynyl group, (9) a C haloalkoxy group, or (10) a hydroxyl group; when n is 2 or more, a plurality of R 3 may be the same or different, and two R 3 represents a C1-6 alkyl group, it may be taken together with the carbon atom to which it is attached to form a C3-6 cycloalkyl group, ring1 represents a 3- to 15-membered cyclic group, R 4 is (1) a halogen atom, (2) a C1-6 alkyl group, (3) a C2-6 alkenyl group, (4) a C2-6 alkynyl group, (5) a C1-6 alkoxy group, (6) a C1-6 haloalkyl group, (7) a C2-6 haloalkenyl group, (8) a C2-6 haloalkynyl group, (9) a C1-6 haloalkoxy group, (10) a C1-6 alkylthio group, (11) a C1-6 alkylsulfinyl group, (12) a C1-6 alkylsulfonyl group, (13) a C2-6 acyl group, (14) a 3- to 6-membered cyclic group, (15) -L R4 -(3- to 6-membered cyclic group), (16) hydroxyl group, (17) nitro group, (18) cyano group, (19) oxo group, (20) -NR 401 R 402 , (21)-COOR 403 , (22)-CONR 404 R 405 , or (23)-SO 2 NR 406 R 407 wherein 1 to 2 carbon atoms in the C1-6 alkyl group, C2-6 alkenyl group, C2-6 alkynyl group, C1-6 alkoxy group, C1-6 haloalkyl group, C2-6 haloalkenyl group, C2-6 haloalkynyl group, C1-6 haloalkoxy group, C1-6 alkylthio group, C1-6 alkylsulfinyl group, C1-6 alkylsulfonyl group, or C2-6 acyl group may be replaced by an oxygen atom or an optionally oxidized sulfur atom, and when p is 2 or more, a plurality of R 4 may be the same or different, R 4 Among these, groups (2) to (15) are each a group having 1 to 9 R 408 and R 408 is (1) a halogen atom, (2) a C1-4 alkyl group, (3) a C1-4 alkoxy group, (4) a C2-6 acyl group, (5) a C3-6 cycloalkyl group, (6) a hydroxyl group, or (7) -NR 409 R 410 represents R 408 When two or more R are substituted, 408 may be the same or different, and L R4 (1) -O-, (2) -(C1-4 alkylene)-, (3) -O-(C1-4 alkylene)-, (4) -(C1-4 alkylene)-O-, (5) -NR 411 -, (6) -S-, (7) -SO-, or (8) -SO 2 represents -, R 401 , R 402 , R 403 , R 404 , R 405 , R 406 , R 407 , R 409 , R 410 , or R 411 each independently represent (1) a hydrogen atom, (2) a C1-6 alkyl group, (3) a C2-6 acyl group, or (4) a C1-6 alkylsulfonyl group, m represents an integer of 0 to 2, n represents an integer of 0 to 5, and p represents an integer of 0 to 5, or a pharmaceutically acceptable salt thereof.

2. Ring 1 is the following ring structure: (In the formula, * indicates the bonding position with the carbonyl group, and the hydrogen atom represented by NH is R 4 2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:

3. R 4 is (1) a halogen atom, (2) a C1-6 alkyl group, (3) a C1-6 alkoxy group, (4) a C1-6 haloalkyl group, (5) a C1-6 haloalkoxy group, (6) a cyclopropyl group, (7) a benzene ring, (8) a pyridine ring, or (9) -COOCH 3 2. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein (10) is -COOtBu, or (11) a cyano group.

4. R 2 is (1) a C1-6 alkyl group, (2) a C1-6 alkoxy group, (3) a C1-6 haloalkyl group, or (4) a C1-6 haloalkoxy group, or a pharmaceutically acceptable salt thereof.

5. The compound represented by general formula (I) is a compound represented by general formula (I-1): (In the formula, R 2-1 represents (1) a C1-6 alkyl group, (2) a C1-6 alkoxy group, (3) a C1-6 haloalkyl group, or (4) a C1-6 haloalkoxy group; R 4-1 is (1) a halogen atom, (2) a C1-6 alkyl group, (3) a C1-6 alkoxy group, (4) a C1-6 haloalkyl group, (5) a C1-6 haloalkoxy group, (6) a cyclopropyl group, (7) a benzene ring, (8) a pyridine ring, or (9) -COOCH 3 , (10) -COOtBu, or (11) a cyano group, and ring1-1 represents the following ring structure: (In the formula, * indicates the bonding position with the carbonyl group, and the hydrogen atom represented by NH is R 4-1 2. The compound according to claim 1, wherein the ring structure is selected from the group consisting of: (R), (C), (D), (E), (F), (H), (I ...

6. The compound represented by general formula (I) is (1) [(3aS,4R,6aR)-4-[(6-bromo-3-pyridazinyl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl](6,7-dihydro-4H-thieno[3,2-c]pyran-2-yl)methanone, (2) [(3aS,4R,6aR)-4-[(6-bromo-3-pyridazinyl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl](5-methyl-2-thienyl)methanone, (3) [(3aS,4R,6aR)-4-[(6-bromo-3-pyridazinyl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl](2-methyl-2H-thieno[3,2-c]pyrazol-5-yl)methanone, (4) [(3aS,4R,6aR)-4-[(6-bromo-3-pyridazinyl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl](6-methylpyrazolo[5,1-b][1,3]thiazol-2-yl)methanone, (5) [(3aS,4R,6aR)-4-[(6-bromo-3-pyridazinyl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl](2-cyclopropyl-2H-thieno[3,2-c]pyrazol-5-yl)methanone (6) [(3aS,4R,6aR)-4-[(6-bromo-3-pyridazinyl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl][2-(difluoromethyl)-2H-thieno[3,2-c]pyrazol-5-yl]methanone, (7) [(3aS,4R,6aR)-4-[(6-bromo-3-pyridazinyl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl](6-fluoro-1,3-benzothiazol-2-yl)methanone, (8) [(3aS,4R,6aR)-4-[(6-bromo-3-pyridazinyl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl][5-(difluoromethyl)-2-thienyl]methanone, (9) [(3aS,4R,6aR)-4-[(6-bromo-3-pyridazinyl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl](thieno[3,2-c]pyridin-2-yl)methanone, (10) [(3aS,4R,(6aR)-4-[(6-bromo-3-pyridazinyl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl](thieno[3,2-b]furan-5-yl)methanone, (11) [(3aS,4R,6aR)-4-[(6-bromo-3-pyridazinyl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl](1-methyl-1H-thieno[2,3-c]pyrazol-5-yl)methanone, (12) 5-{[(3aS,4R,6aR)-4-[(6-bromo-3-pyridazinyl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl]carbonyl}-2-methyl-3-thiophenecarbonitrile, (13) 2-methyl-2-propanyl 2-[(3aS,4R,6aR)-4-[(6-bromo-3-pyridazinyl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl]carbonyl}-6,7-dihydro[1,3]thiazolo[4,5-c]pyridine-5(4H)-carboxylate, (14) methyl 2-[(3aS,4R,6aR)-4-[(6-bromo-3-pyridazinyl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl]carbonyl}-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-carboxylate, (15) [(3aS,4R,6aR)-4-[(6-bromo-3-pyridazinyl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl](2-phenyl-2H-thieno[3,2-c]pyrazol-5-yl)methanone, (16) [(3aS,4R,6aR)-4-[(6-bromo-3-pyridazinyl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl][2-(3-pyridinyl)-2H-thieno[3,2-c]pyrazol-5-yl]methanone, (17) [(3aS,4R,6aR)-4-[(6-bromo-3-pyridazinyl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl](4,5-dimethyl-1,3-thiazol-2-yl)methanone, (18) methyl 2-[(3aS,4R,6aR)-4-[(6-bromo-3-pyridazinyl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl]carbonyl}-4,7-dihydrothieno[2,3-c]pyridine-6(5H)-carboxylate, (19) [(3aS,4R,6aR)-4-[(6-bromo-3-pyridazinyl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl](4,5,7,8-tetrahydrothieno[2,3-d]oxepin-2-yl)methanone, (20) [(3aS,4R,6aR)-4-[(6-bromo-3-pyridazinyl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl][5-(2-fluoroethoxy)-2-thienyl]methanone, (21) [(3aS,4R,6aR)-4-[(6-bromo-3-pyridazinyl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl](4-fluoro-5-methyl-2-thienyl)methanone, (22) [(3aS,4R,6aR)-4-[(6-chloro-3-pyridazinyl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl](6,7-dihydro-4H-thieno[3,2-c]pyran-2-yl)methanone, (23) [(3aS,4R,6aR)-4-{[6-chloro-4-(trifluoromethyl)-3-pyridazinyl]oxy}hexahydrocyclopenta[c]pyrrol-2(1H)-yl](6,7-dihydro-4H-thieno[3,2-c]pyran-2-yl)methanone, (24) {4-[(5-chloropyrido[2,3-d]pyridazin-8-yl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl}(6,7-dihydro-4H-thieno[3,2-c]pyran-2-yl)methanone, (25) {4-[(4-chlorothieno[2,3-d]pyridazin-7-yl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl}(6,7-dihydro-4H-thieno[3,2-c]pyran-2-yl)methanone, (26) [(3aS,4R,6aR)-4-[(6-chloro-5-methoxy-3-pyridazinyl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl](6,7-dihydro-4H-thieno[3,2-c]pyran-2-yl)methanone, (27) [(3aS,4R,6aR)-4-[(6-chloro-4-methoxy-3-pyridazinyl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl](6,7-dihydro-4H-thieno[3,(2-c]pyran-2-yl)methanone, (28) [(3aS,4R,6aR)-4-[(6-chloro-3-pyridazinyl)oxy]hexahydrocyclopenta[c]pyrrol-2(1H)-yl](2-methyl-2H-thieno[3,2-c]pyrazol-5-yl)methanone, (29) [(3aS,4S,6aR)-4-[(6-bromo-3-pyridazinyl)oxy]tetrahydro-1H-spiro[cyclopenta[c]pyrrole-5,1′-cyclopropane]-2(3H)-yl](6,7-dihydro-4H-thieno[3,2-c]pyran-2-yl)methanone, (30) [(3aS,4R,6aR)-4-[(6-bromo-3-pyridazinyl)oxy]-3a-methylhexahydrocyclopenta[c]pyrrol-2(1H)-yl](6,7-dihydro-4H-thieno[3,2-c]pyran-2-yl)methanone, (31) [(3aS,4S,6aR)-4-[(6-bromo-3-pyridazinyl)oxy]-5,5-dimethylhexahydrocyclopenta[c]pyrrol-2(1H)-yl](6,7-dihydro-4H-thieno[3,2-c]pyran-2-yl)methanone, (32) [(3aR,4R,6aS)-4-[(6-bromo-3-pyridazinyl)oxy]-3a-hydroxyhexahydrocyclopenta[c]pyrrol-2(1H)-yl](6,7-dihydro-4H-thieno[3,2-c]pyran-2-yl)methanone, (33) [(3aR,4R,6aS)-4-[(6-bromo-3-pyridazinyl)oxy]-3a-methoxyhexahydrocyclopenta[c]pyrrol-2(1H)-yl](6,7-dihydro-4H-thieno[3,2-c]pyran-2-yl)methanone, and (34) The compound according to claim 1, which is a compound selected from the group consisting of [(3aS,4S,5S,6aR)-4-[(6-bromo-3-pyridazinyl)oxy]-5-fluorohexahydrocyclopenta[c]pyrrol-2(1H)-yl](6,7-dihydro-4H-thieno[3,2-c]pyran-2-yl)methanone, or a pharmaceutically acceptable salt thereof.

7. A pharmaceutical composition comprising the compound according to any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, as an active ingredient, and further comprising a pharmaceutically acceptable carrier.

8. The pharmaceutical composition according to claim 7, which is an ABHD6 inhibitor.

9. The pharmaceutical composition according to claim 7, which is an agent for treating and / or preventing a disease associated with ABHD6.

10. The pharmaceutical composition according to claim 9, wherein the ABHD6-associated disease is pain, a neurological disease, an inflammatory disease, an autoimmune disease, a metabolic disease, or a malignant tumor.

11. The pharmaceutical composition according to claim 9, wherein the disease associated with ABHD6 is pain, and the pain is pain associated with osteoarthritis, cancer pain, pain associated with chemotherapy, chronic lower back pain, lower back pain associated with osteoporosis, bone fracture pain, pain associated with rheumatoid arthritis, neuropathic pain, post-herpetic pain, pain associated with diabetic neuropathy, fibromyalgia, pain associated with pancreatitis, pain associated with interstitial cystitis / bladder pain syndrome, pain associated with endometriosis, pain associated with irritable bowel syndrome, migraine, or pain associated with dental pulpitis.

12. The pharmaceutical composition of claim 9, wherein the ABHD6-associated disease is a neurological disease, and the neurological disease is tremor, dyskinesia, dystonia, spasticity, compulsive and obsessive-compulsive behavior, depression, anxiety disorder, panic disorder, acute stress reaction, post-traumatic stress disorder, obsessive-compulsive disorder, agoraphobia, social phobia, mood disorder, epilepsy, traumatic brain injury, spinal cord injury, multiple sclerosis, encephalomyelitis, Parkinson's disease, Huntington's chorea, Alzheimer's disease, or sleep disorder.

13. The pharmaceutical composition according to claim 7, which is administered in combination with at least one selected from the group consisting of acetaminophen, nonsteroidal anti-inflammatory drugs, opioid drugs, antidepressants, antiepileptic drugs, N-methyl-D-aspartic acid antagonists, muscle relaxants, antiarrhythmic drugs, steroid drugs, and bisphosphonate drugs.

14. A therapeutic and / or preventive agent for ABHD6-associated diseases, comprising the compound according to any one of claims 1 to 6 or a pharmaceutically acceptable salt thereof.

15. A method for preventing and / or treating an ABHD6-associated disease, comprising administering to a patient in need thereof a compound according to any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing either one as an active ingredient and a pharmaceutically acceptable carrier.

16. A compound according to any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, for use in the prevention and / or treatment of an ABHD6-associated disease.

17. Use of a compound according to any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, for the manufacture of an agent for the prophylaxis and / or treatment of a disease associated with ABHD6.